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According to epidemiological data people with type 2 diabetes have a 50% increased risk of 
developing colorectal cancer. Hyperinsulinemia, which occurs in type 2 diabetes, is considered 
to be a factor linking these two diseases. One mechanism by which exposure to higher and 
more sustained levels of insulin might encourage tumourigenesis is by driving metabolic 
reprogramming in colorectal cells. As such, the aim of this investigation is to examine the 
impact of insulin exposure on metabolic reprogramming in colorectal tumour cells.  
In order to address this aim, assays were performed to assess the effect of insulin on tumour 
cell proliferation across the progressive stages of carcinogenesis. Early adenoma cells were 
found to be the most sensitive to insulin exposure in comparison to cell line models of the later 
stages of carcinogenesis. In the next part of this study, stable isotope tracer analysis (SITA), 
western blotting and quantitative real time PCR were performed to examine the changes in 
metabolic pathways upon insulin stimulation in early and late stage cells. Data obtained from 
SITA showed that insulin increases the levels of glycolysis in both cell lines tested. The results 
of western blotting and quantitative real time PCR suggest that insulin may promote aerobic 
glycolysis in tumour cells by increasing PDK1 expression via HIF1α. In addition, SITA showed 
that insulin increased glutamine anaplerosis and amino acid uptake in the early stage cells 
exclusively. This result may explain how insulin induces an increase in proliferation in early but 
not late stage cells.    
Together, the results of this investigation suggest that insulin exposure may encourage tumour 
progression by promoting metabolic reprogramming in colorectal tumour cells. However, 
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APC - Adenomatous Polyposis Coli 
ASCT2 - Alanine, Serine, Cysteine Transporter 2  
ATP - adenosine triphosphate  
BAD – BCL2-associated agonist of cell death 
CK1 - casein kinase 1 
C1- AA/C1 cell line  
CI – mitochondrial electron transport chain complex 1 
CII – mitochondrial electron transport chain complex 2 
CIII – mitochondrial electron transport chain complex 3 
CIV – mitochondrial electron transport chain complex 4 
Dvl – dishevelled  
EGFR – epidermal growth factor receptor  
ETC –  electron transport chain  
FADH2 - flavin adenine dinucleotide 
FOXO – forkhead box protein O 
GLUT1 – glucose transporter 1  
GLUT4 – glucose transporter 4  
Grb2 - Growth factor receptor-bound protein 2 
GSK3 – glycogen synthase kinase-3 
IR – insulin receptor  
IRS – insulin receptor substrate  
LDH – lactate dehydrogenase  
LDHA – lactate dehydrogenase A  
M – AA/C1/SB/10C/M cell line 
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MPC – mitochondrial pyruvate carrier 
mTORC1 – mammalian target of rapamycin complex 1 
NADH - nicotinamide adenine dinucleotide – hydrogen 
OAA – Oxaloacetate 
PDK1 – pyruvate dehydrogenase kinase 
PIP2 - phosphatidylinositol-2-phosphate 
PIP3 - phosphatidylinositol-3-phosphate 
PKM1 - pyruvate kinase isozymes M1 
PKM2 - pyruvate kinase isozymes M2 
PI3K - phosphatidylinositol-3-kinase  
PTEN - Phosphatase and tensin homolog  
qPCR – quantitative real time polymerase chain reaction  
SB – AA/C1/SB cell line 
SERBP – sterol regulatory element-binding protein 1 
SITA – stable isotope tracer analysis 
SOS -  son of sevenless  
S6 – ribosomal S6 kinase 
TCA cycle - tricarboxylic Acid Cycle 
TP53 – tumour protein 53  
T2DM – type 2 diabetes mellitus 
4EBP – eukaryotic translation initiation factor 4E-binding protein 
10C – AA/C1/SB/10C cell line  
α-KG - α-ketoglutarate 
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Chapter 1: Introduction 
 
1.1. Colorectal Cancer Incidence  
Colorectal cancer is the third most common cancer worldwide (1) with 1.2 million people 
diagnosed every year (2). It accounts for approximately 10% of cancer associated death in 
industrialized countries. Incidence of colorectal cancer varies geographically with around 50% 
of cases in developed parts of the world. Higher prevalence of colorectal cancer in higher 
income countries has been linked to western lifestyle including unhealthy diet, smoking, low 
physical activity and high obesity rates (2).  
According to the National Cancer Registration and Analysis Service (NCRAS), 50.7% of 
colorectal cancer patients in England will be alive five years after diagnosis (3). However, the 
survival rate depends on the stage of disease at diagnosis. The five year survival rate for 
people diagnosed with the first stage of disease (Dukes A) is 93.2%, whereas for people 
diagnosed with advanced disease (Dukes D) it drops to 6.6% (3). Therefore, early diagnosis 
of colorectal cancer is crucial to improve outcomes. In England, bowel cancer screening is 
offered every two years to people from 60 to 74 years old (4). People above this age can 
request a screening kit every two years (4). In addition, a one-off test is offered to people at 
the age of 55 (4). A statistical analysis performed by the Cancer Research UK showed that 
colorectal cancer incidence in people aged 60-74 has decreased by 5% since early 1990s (5).    
Although the incidence of colorectal cancer in older people is decreasing, because of large 
scale screening programs (6), the number of young adults suffering with colorectal cancer is 
getting higher (7). A statistical analysis performed on 143.7 million people from 20 European 
countries has shown that incidence of colorectal cancer increased with 7.9% per year among 
people aged 20-29 years old between 2004 and 2014 (7). In the UK, colorectal cancer 
incidence in people aged 25-49 has increased by 39% since early 1990s (5).  
The rise in colorectal cancer incidence in young people may be caused by lack of screening 
programs as well as lifestyle factors such as poor eating habits and lack of exercise (8). For 
example, unhealthy diet and sedentary lifestyle often lead to obesity and diabetes, which has 
been associated with increased risk of developing colorectal cancer by numerous studies (9–
12). It is important to understand the molecular mechanisms underlying colorectal cancer in 




1.2. Hereditary Colorectal Cancer Syndromes   
Colorectal cancers are usually sporadic, however, around 5% of cases occur as a result of 
inherited mutations (13). The most common hereditary syndromes giving predisposition to 
colorectal cancer are Lynch syndrome and Familial Adenomatous Polyposis (FAP) (13). 
1.2.1. Lynch Syndrome  
Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is 
caused by a germ line mutation in DNA mismatch repair genes (MMR). In 90% of cases 
mutations occur in MSH1 and MSH2 genes. Less commonly mutations may be found in other 
MMR genes such as: MSH6, PMS2, and EPCAM. As a consequence of impaired DNA MMR 
machinery, any secondary mutations remain unrepaired and increase the risk of developing 
cancers (14). Lynch syndrome patients have about 80% lifetime risk of developing colorectal 
cancer (15). They are diagnosed with colorectal cancer at the age of 45 on average (15), which 
is about two decades earlier than for sporadic colorectal cancer (16). Besides colorectal 
cancer, Lynch syndrome has been shown to increase the risk of developing other cancers 
such as endometrial, ovarian, stomach and urinary tract (17).      
1.2.2. Familial Adenomatous Polyposis  
FAP is characterized by the development of numerous benign polyps in the colon and rectum 
in early life. Those polyps are usually asymptomatic, but some of them will eventually progress 
and give rise to colorectal cancer (18). The median age when FAP patients develop colorectal 
cancer is 40 (7). FAP is an autosomal dominant disorder caused by a mutation in Adenomatous 
Polyposis Coli (APC) gene (18). APC mutation is one of the most important triggers of 
colorectal cancer, not only in FAP, but also in sporadic cases. It occurs in 90% of all colorectal 
cancer cases in the early stages of tumorigenesis (19).   
1.3. Spontaneous Colorectal Cancer - Mutations  
Colorectal cancer is a multistage process, following an adenoma to carcinoma sequence. 
Tumorigenesis begins in the crypts of the colonic epithelium and subsequently gives rise to 
benign adenomas, which gradually advance into invasive carcinomas. This step-wise tumour 
progression is accompanied by an ordered sequence of genetic mutations and epigenetic 







Figure 1. Colorectal tumour progression. Diagram represents stages of colorectal tumour 
development and mutations associated with particular stages. Mutations in APC and β-catenin 
appear early in tumourigenesis. At the stage of adenoma, mutations in Ras or Raf proteins are 
often visible. Mutations in PI3K, p53, PTEN occur later on during tumour progression. Diagram 
adapted from (21,22).   
 
1.3.1. APC and Wnt signalling pathway 
Inactivation of the APC tumour suppressor gene is the most common initiating event in the 
majority of colorectal cancers (23). APC mutation leads to constitutive activation of the Wnt 
signalling pathway, which is thought to be a key driver of colorectal cancer (23). Under normal 
conditions, the role of Wnt signalling is to maintain epithelial stem cell populations, which reside 
at the bottom of the colonic crypts (23). Constitutive Wnt signalling, which occurs in cancer, 
leads to the retention of the stem cell phenotype, as a result undifferentiated cells accumulate 
and start forming benign polyps (23). Two models of Wnt signalling have been proposed: the 
canonical and non-canonical model (24). 
1.3.1.1. Canonical model of Wnt signalling  
According to the canonical model, in the absence of the Wnt ligand binding to the Frizzled 
receptor, a destruction complex composed of APC, glycogen synthase kinase 3 (GSK3), the 
scaffolding protein Axin, casein kinase (CK1), and Dishevelled (Dvl) binds and phosphorylates 
β-catenin in the cytosol (24). Phosphorylated β-catenin is targeted for ubiquitination by E3-
ubiquitin ligase β-TrCP and degradation via proteasome. In the presence of Wnt ligands, Axin 
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binds to the phosphorylated low density lipoprotein receptor related protein 5/6 (LRP5/6). As a 
result, destruction complex disassembles and β-catenin is stabilized. β-catenin accumulates 
in the cytoplasm and translocates to the nucleus, where it activates T-cell factor (TCF) and the 
lymphoid enhancer factor (LEF) family of transcription factors and up-regulates Wnt signalling 
target genes expression (24) (Figure 2).  
1.3.1.2. Non-canonical model of Wnt signalling  
An alternative model of Wnt signalling was proposed after investigating the endogenous 
destruction complex components (25). According to this model, in the absence of Wnt ligand 
binding, the destruction complex binds, phosphorylates and ubiquitinates β-catenin by β-TrCP 
(24). Subsequently, the proteasome degrades β-catenin and as a result recycles the 
destruction complex. In contrast to the canonical model, a non-canonical model shows that 
upon Wnt ligand binding, the whole, intact destruction complex is recruited by the LRP receptor 
where it binds and phosphorylates β-catenin. However, the ubiquitination of β-catenin by β-
TrCP is blocked, therefore newly synthesized β-catenin accumulates in the cytosol (24) (Figure 
2).  
 
Figure 2. Canonical and non-canonical models of Wnt signalling. A. Canonical model of 
Wnt signalling: In the absence of Wnt ligand binding to the Frizzled receptor, the destruction 
complex binds β-catenin and targets it for ubiquitination by βTrCP. Ubiquitinated β-catenin is 
targeted for degradation via the proteasome. Wnt ligand binding to the Frizzled receptor leads 
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to Axin recruitment to the LRP receptor, disassembly of the destruction complex and 
accumulation of β-catenin in the cytoplasm. B. Non-canonical model of Wnt signalling: In the 
absence of Wnt ligand binding to Frizzled receptor, destruction complex binds β-catenin and 
ubiquitinates it by β-TrCP. Ubiquitinated β-catenin is targeted for degradation via proteasome. 
When Wnt ligand binds to the receptor destruction complex is recruited to LRP receptor. Β-
catenin is bound by destruction complex, howeve, ubiquitination of β-catenin is blocked, 
therefore it accumulates in the cytoplasm. Figure adapted from (24).  
98% of mutations in the APC gene are loss of function mutations (frameshifts or nonsense 
mutations) leading to formation of truncated APC protein (26). As a result the destruction 
complex cannot be fully formed (26). That leads to accumulation of β-catenin and sustained 
upregulation of Wnt target genes such as c-myc, LEF-1, matrix metalloproteinase MMP-7(27). 
In sporadic colorectal cancers with a wild type APC, there is often a mutation directly in the β-
catenin gene which leads to sustained Wnt signalling (26).  
1.3.2. MAPK signalling pathway  
Another important pathway which is often mutated in colorectal tumours is the MAPK signalling 
pathway. This pathway starts with a growth factor binding to a trans-membrane receptor called 
Epidermal Growth Factor Receptor (EGFR). This leads to the recruitment and activation of the 
GRB2/SOS complex, which subsequently activates Ras. RAS is a small GTPase protein which 
induces activation of a kinase cascade starting with RAF and followed by MEK and Erk (28)  
(Figure 3) . Around 30-50% and 5-10% of colorectal tumours harbour a mutation in KRAS and 
BRAF oncogenes respectively (29). Mutations in this pathway result in constitutive up-
regulation of growth promoting genes (30).  
1.3.3. PI3K/Akt signalling pathway  
EGFR stimulation also leads to activation of the PIK3CA oncogene, which encodes the p110α 
subunit of phosphatidylinositol 3-kinase (PI3K) (30). Activated PI3K converts 
phosphatidylinositol-2-phosphate (PIP2) to phosphatidylinositol-3-phosphate (PIP3) and results 
in phosphorylation and activation of Akt. Akt activation triggers numerous molecular pathways 
resulting in proliferation, migration, cell survival and angiogenesis (30). Akt can be switched 
off by the PTEN tumour suppressor protein which dephosphorylates and converts PIP3 back 
to PIP2. PI3K and PTEN are often mutated in colorectal cancer resulting in constitutive 
activation of the Akt signalling pathway (30). PI3K/Akt pathway is able to influence cellular 
metabolism is via activation of its downstream target – mTORC1 (31). In non-transformed cells, 
mTORC1 senses the energy status of a cell and in the presence of nutrients responds by 
driving anabolic processes such as protein synthesis, nucleic acid synthesis and lipogenesis 
(32). The outcome of these reactions is production of building blocks necessary for cell growth 
(32). In cancer cells with deregulated activation of the PI3K/Akt pathway, there is a constitutive 
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stimulation of mTORC1. This results in high levels of biomass production which is used to 




Figure 3. Signalling pathways involved in colorectal cancer development. Ligand binding 
to the EGFR receptor activates PI3K, which drives conversion of PIP2 to PIP3. PIP3 activates 
Akt, which triggers activation of mTORC1. Activation of EGFR also recruits Shc and Grb2. 
Grb2 activates SOS, which drives a kinase cascade leading to activation of Erk. Proteins 
commonly mutated in colorectal cancer are indicated in red.  
 
1.3.4. TP53 tumour suppressor gene   
Another common mutation occurs in the TP53 tumour suppressor gene. TP53 is responsible 
for the induction of G1 cell cycle arrest and DNA repair before allowing cells to enter S phase 
(26). Upon failure to repair DNA, p53 is responsible for inducing apoptosis (26). It is thought 




1.4. Metabolic reprogramming in cancer  
During the multistep colorectal tumour progression, mutations discussed above drive the 
hallmarks of cancer (Figure 4). For example, a constitutive activation of MAPK and Akt 
signalling pathways leads to sustained growth promoting signals and uncontrolled proliferation 
(33). Activation of Wnt signalling results in expression of such genes as MMP-7(27), which 
promote tissue invasion and metastasis (34) and inactivating mutations in TP53, a tumour 
suppressor gene, lead to evasion of apoptosis (33).  
This study is focused on one hallmark of cancer in particular, that is metabolic reprogramming. 
Metabolic reprogramming was classified as a hallmark of cancer by Hanahan and Weinberg 
in 2011 (35). The alterations in cellular metabolism are necessary to provide energy and 
building blocks to support chronic proliferation (35). Multiple oncogenic pathways involved in 







Figure 4. The hallmarks of cancer cells. Figure presents ten hallmark characteristics of 
cancer cells. Cancer cells develop these capabilities as a result of acquired mutations. Adapted 
from (36).   
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1.4.1. The key metabolic pathways used by cancer cells  
Metabolism is defined as a collection of all the chemical reactions within a cell, which produce 
and release energy in order to sustain life. Metabolic reactions can be divided into three 
categories: catabolic, by which cells produce energy, anabolic, used for biosynthesis, and 
waste disposal necessary to get rid of toxic by-products (37). The main metabolic pathways 
used by cells to produce energy are glycolysis, the TCA cycle and oxidative phosphorylation 
(37). As mentioned above, metabolic reprogramming has been defined as a hallmark of cancer 
cells (35). This is where cancer cells up- or down-regulate certain metabolic pathways in order 
to maximize energy production and biomass synthesis to support chronic proliferation (38). 
 
1.4.2. The Warburg effect  
One of the most common characteristics of cancer cell metabolism is elevated levels of 
glycolysis regardless of oxygen availability, this is known as the Warburg effect (39). In the 
1920s, Otto Warburg observed that tumour cells consume large amounts of glucose compared 
to surrounding tissue (39). In addition, he noticed that glucose taken up by tumour cells was 
converted into lactate in the presence of oxygen (39). Nowadays, the Warburg effect is 
considered to be one of a key differences between quiescent and tumour cells (40). In 
quiescent cells, glycolysis occurs at a basal level and most energy is produced via oxidative 
phosphorylation (40). Glycolysis is not an efficient form of metabolism as it only allows for the 
production of two ATP molecules per cycle (40). By contrast, 36 molecules of ATP are 
produced via the TCA cycle (Figure 5) (40). Regardless of the energy inefficiency tumour cells 
increase their levels of glycolysis and predominantly convert the resulting pyruvate into lactate 
rather than oxidize it in the TCA cycle (40). Warburg hypothesized that this behaviour of tumour 
cells is caused by damaged mitochondria (41). Today, we know that mitochondrial activity is 
intact in most cancer cells (42). Currently, the most popular theory states that the Warburg 
effect is used to produce metabolic intermediates necessary for biosynthetic processes (41). 
Glycolytic intermediates supply such biosynthetic pathways as the hexosamine pathway, the 
pentose phosphate pathway and one carbon metabolism (43). As a result there is increased 
synthesis of amino acids, nucleotides and lipids, which are essential building blocks needed 
for cell growth (43).  
 
The principle of the Warburg effect has been used to develop a method of tumour detection 
called fluorodeoxyglucose positron emission tomography (FDG-PET) (44). FDG-PET is a non-
invasive method of tumour detection, staging and monitoring (45). Fluorine-18 
fluorodeoxyglucose (FDG) is a glucose analogue used as a tracer, this allows clinicians to 





Figure 5. Diagram representing differences in cellular metabolism in quiescent and 
tumour cells. In quiescent cells, when there is oxygen available, pyruvate, produced as a 
result of glycolysis, enters the TCA cycle. Most of the energy is produced via oxidative 
phosphorylation. When there is no oxygen available, pyruvate is converted into lactate and 
anaerobic glycolysis occurs. In proliferative tissue or tumour cells, pyruvate is converted into 
lactate regardless of oxygen availability. That is known as aerobic glycolysis or the Warburg 
effect. Figure adapted from (40).  
 
 
Below I describe how different mutations drive metabolic reprogramming in tumour cells, these 
are summarised in Figure 6:  
 
1.4.2.1. Changes in PKM2 expression  
One of the mechanisms that promotes the Warburg effect in cells is the expression of a specific 
isoform of pyruvate kinase (PK) – PKM2. PK is a glycolytic enzyme responsible for the 
conversion of phosphoenolpyruvate (PEP) to pyruvate (44) (Figure 6). There are two splice 
variants of PK; PKM1 and PKM2 (46). Splice variant M2 is less efficient at converting PEP to 
pyruvate. As a result pyruvate is produced at a lower rate so more of the glycolytic 
intermediates upstream of PEP build up and can be used for biosynthetic pathways (44). PKM2 
expression is often increased in colorectal cancers. Moreover, high expression of PKM2 has 
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been associated with poor prognosis in colorectal cancer patients. It has also been shown in 
in vitro models that PKM2 knockdown in colorectal cancer cells increases the efficacy of the 
chemotherapeutic, 5-flurouracil (5-FU).  
 
1.4.2.2. Changes in LDHA expression  
Another glycolytic enzyme which has been reported to be overexpressed in numerous cancers 
is lactate dehydrogenase A (LDHA). LDHA facilitates the conversion of pyruvate to lactate and 
converts NADH to NAD+ in the process (47). It has been found that high expression of LDHA 
promotes many characteristics of the tumour cell phenotype. It has been observed that tumour 
cells with down-regulated LDHA activity are not able to maintain high ATP levels. This resulted 
in decreased proliferation of tumour cells in normoxic and hypoxic conditions (48). In addition, 
LDHA overexpression promotes invasion and migration. It has been found that there is a 
positive correlation between LDHA expression and distant metastasis of colorectal cancer (49).  
 
1.4.2.3. Changes in GLUT1 expression  
Glucose transporter 1 (GLUT1) is another protein that when elevated may facilitate the 
Warburg effect. GLUT1 is encoded by the SLC2A1 gene and it functions to transport glucose 
molecules across the plasma membrane into cells. It has been reported to be overexpressed 
in many types of cancer, for example in colorectal cancer (50). Moreover, it has been shown 
by Shen et al. that the expression of GLUT1 is increased in colorectal tumours with mutated 
KRAS. In addition, overexpression of GLUT1 has been associated with poor prognosis in most 
solid tumours (50) including colorectal cancer (51).  
 
1.4.2.4. Changes in MPC expression 
Loss of mitochondrial pyruvate carrier (MPC) expression is another way tumour cells shift 
metabolism towards increased glycolysis. The role of the MPC is to transfer pyruvate from the 
cytosol across the mitochondrial membrane. The MPC protein consists of two subunits; MPC1 
and MPC2 that are encoded by the MPC1 and MPC2 genes (52). As a results of decreased 
expression of one or both MPC subunits less pyruvate enters mitochondria. That promotes 
pyruvate conversion into lactate and the Warburg effect. Reduced expression of MPC1 
positively correlates with poorer prognosis in colorectal cancer (53).   
 
1.4.2.5. Changes in PDK1 expression  
Increased expression of pyruvate dehydrogenase kinase 1 (PDK1) can also promote the 
Warburg effect. PDK1 inhibits pyruvate dehydrogenase (PDH), an enzyme which converts 
pyruvate into acetyl-CoA; one of the major TCA cycle carbon sources. As a result of PDH 
inhibition, pyruvate is diverted to lactate instead and the levels of glycolysis are increased, 
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contributing to the Warburg effect (54). PDK1 overexpression has been shown to promote a 
malignant phenotype in many cancer types. For example, Liu et al. has reported that elevated 
expression of PDK1 increases cell proliferation and mobility as well as inhibiting apoptosis in 
non-small cell lung cancer (NSCLC) (55). In addition, Nam et al. has shown that PDK1 levels 
are increased in the HT29 colorectal cancer cell line and that it is one of the proteins involved 
in driving aerobic glycolysis in this colorectal cancer cell line (56). Moreover, Wnt signalling 
has been found to affect PDK1 expression levels in colorectal tumour cells. In 2014, Pate et 
al. showed that dysregulation of Wnt signalling in cells increases the level of glycolysis. In 
addition, they identified that PDK1 is a direct target of Wnt signalling (57). Due to the fact that 
the role of PDK1 is to inhibit carbon entry into the TCA cycle, the levels of glycolysis in cells 
harbouring this mutation are increased, contributing to the Warburg effect (54).  
 
1.4.2.6. Changes in HIF1α expression  
Hypoxia inducible factor 1α (HIF1α) is an important regulator of many metabolic proteins and 
enzymes involved in facilitating the Warburg effect. It is known to play a role in supporting 
tumour cell proliferation during hypoxia. However, in normoxic conditions HIF1α has been 
recognized to support metabolic reprogramming by positively regulating expression of 
numerous proteins including PKM2, LDHA, GLUT1 and PDK1. Overexpression of HIF1α has 
been reported to be positively correlated with poorer prognosis in colorectal cancer patients 
(58).  
 
1.4.3. Oxidative metabolism   
Although glycolysis is upregulated in cancer cells, this is often not at the expense of oxidative 
metabolism. TCA cycle metabolism and ATP production in the mitochondria remain important 
for tumour cells. The TCA cycle not only produces energy, but also provides intermediates for 
fatty acid and amino acid synthesis (59). These molecules serve as building blocks for rapidly 
dividing cells (60). For example, fatty acids are the most important component of the cell 
membrane. In addition, fatty acid derivatives are used in cell signalling (60). Amino acids serve 
as building blocks for proteins, messengers for intercellular communication as well as energy 
generating metabolites (61). In addition, the TCA cycle provides precursors for nicotinamide 
adenine dinucleotide (NADH) synthesis, which is then used for energy production in the 
electron transport chain (ETC) (59).  
 
1.4.3.1. Mutations in TCA cycle metabolic enzymes   
The TCA cycle consists of eight steps, which are catalysed by different enzymes (59). 
Mutations in TCA cycle enzymes such as citrate synthase, succinate dehydrogenase (SDH), 
aconitase, isocitrate dehydrogenase (IDH) and fumarate hydratase (FH) have been reported 
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in numerous cancers (62). These mutations result in aberrant production of TCA cycle 
intermediates, so called oncometabolites (62). For example, IDH is an enzyme, which 
catalyses the conversion of isocitrate to α-ketoglutarate (α-KG) (59). IDH is encoded by two 
genes: IDH1 and IDH2 (59). Mutations can occur in either of these genes, however, they are 
more prevalent at IDH1. Mutated IDH is able to convert α-KG to 2-hydroxyglutarate (2-HG) 
(59). 2-HG has been found to promote development and progression of some cancers, such 
as gliomas, and is considered an oncometabolite (59). Another example of a TCA cycle 
enzyme found to be mutated in cancers is SDH (59). SDH catalyses conversion of succinate 
to fumarate (59) Reduced activity of SDH results in decreased production of fumarate and an 
accumulation of succinate (59). Mutations in an enzyme catalysing conversion of fumarate into 
malate – FH, are also common in some cancers (59). Mutations in FH lead to an accumulation 
of fumarate in cells (59). Fumarate is also considered an oncometabolite (63). Generation of 
oncometabolites such as fumarate, succinate and 2-HG lead to the stabilization of HIF1α (64). 
In normal cells, when oxygen is available HIF1α is hydroxylated by prolyl hydroxylase (PHD) 
and then ubiquitinated by pVHL (the von Hippel-Lindau tumour suppressor protein) and 
degraded (64). Accumulation of oncometabolites inhibits PHD activity. As a result, HIF1α 
cannot be ubiquitinated by pVHL and degraded (64). Activation of HIF1α has multiple effects 
on cellular metabolism as described in section 1.4.2.6.  In this way reprogrammed TCA cycle 
metabolism can drive tumour cell growth and survival (62).  
 
1.4.3.2. Glutamine anaplerosis 
Another important aspect of metabolic reprogramming in cancer is increased uptake of 
glutamine. Glutamine is not only an important source of nitrogen but also a source of energy 
for rapidly proliferating cells. As a result of decreased amounts of glucose entering the TCA 
cycle due to the Warburg effect, carbon from glutamine can fuel the TCA cycle, entering as α-
ketoglutarate (α-KG) and be used to produce ATP (65). This is known as TCA cycle 
anaplerosis. Increased glutaminolysis has been reported in many cancers (66). Glutaminase 
(GLS – the enzyme converting glutamine to glutamine, the first step in glutaminolysis) 
expression and ASCT2 (a glutamine transporter) expression in increased in many cancers 
including colorectal cancer. In addition, mutations in Wnt signalling has been found to promote 
glutamine anaplerosis. This occurs via activation of one of its target genes – c-myc. Myc has 
been shown to increase mitochondrial gene expression and as a result promote mitochondrial 
biogenesis (31). Moreover, it has been demonstrated that overexpression of myc increases 
usage of glutamine by the mitochondria. It does so by enhancing the expression of the 
metabolic enzyme GLS, which deaminates glutamine to produce glutamate. Glutamate can be 






Figure 6. The main metabolic pathways in tumour cells. GLUT1 transports glucose into the 
cells for usage in glycolysis. The pentose phosphate pathway (PPP) branches off glycolysis 
and results in lipid and nucleotide synthesis. The end product of glycolysis – pyruvate is 
transported into the mitochondria where it is converted in acetyl-CoA, which enters TCA cycle. 
NADH and FADH2 produced by TCA cycle are used as electron donors for the electron 









1.5. Diabetes Mellitus  
Diabetes Mellitus is emerging as one of the major global health problems in recent years. 
According to the International Diabetes Federation (IDF), it affects around 425 million adults 
worldwide and its incidence is steadily increasing (67). IDF estimates that the number of 
individuals with diabetes will rise to 629 million by 2045 (67). Currently, diabetes is placed 9th 
as a major cause of reduced life expectancy (68). Diabetes can be divided into two types. Type 
1 diabetes is an autoimmune disease most commonly of juvenile-onset, whereas type 2 
diabetes is a non-insulin dependent metabolic disorder most commonly occurring in adults, 
however earlier and earlier onset is being recorded (69).  
 
1.5.1. Type 2 Diabetes Mellitus  
Type 2 Diabetes Mellitus (T2DM) accounts for 90% of all cases of diabetes (70). Although 
some genetic factors can influence the predisposition to this disease (71), the key drivers are 
environmental (72). The main risk factors for developing diabetes include: obesity, unhealthy 
diet and sedentary lifestyle (72). T2DM is characterized by insulin resistance in insulin 
responsive tissues: liver, skeletal muscle and adipose tissue (73). Insulin resistance leads to 
elevated hepatic glucose production, which results in systemic hyperglycaemia (74). As a 
consequence, pancreatic β cells produce excessive amounts of insulin in order to overcome 
insulin resistance and this leads to hyperinsulinemia (74).   
The pathophysiological disturbances occurring in T2DM lead to abnormal levels of circulating 
metabolites. As a result people with T2DM have an increased risk of developing other health 
issues including cardiovascular disease, blindness, kidney failure (44) and cancer (75). 
1.5.2. Type 2 Diabetes Mellitus and Cancer  
Epidemiological data shows that T2DM increases the risk of developing cancer at various sites 
such as breast, bladder, endometrium, pancreas, colon and rectum. Moreover, several cohort 
studies have indicated that T2DM also increases the risk of cancer related mortality from 
several cancers including endometrial, breast and colorectal (76,77). For example, a 
retrospective cohort study performed by Lipscombe et al. has shown that women with T2DM 
have around 40% greater mortality within first five years after developing breast cancer 
compared to women without diabetes (77). A meta-analysis of observational studies carried 
out by Mills et al. has indicated that people with diabetes and colorectal cancer have a 17% 
increased risk of all-cause mortality and a 12% increased risk cancer-specific mortality (78).      
Cancer and T2DM share common risk factors such as obesity, which may be partially 
responsible for the associations between these two diseases. However, there is accumulating 
evidence that T2DM is an independent risk factor for developing cancer and increased cancer 
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related mortality. Several studies have reported that the association between T2DM and 
cancer is independent of BMI (79–81). Biological associations between diabetes and cancer 
are still poorly understood. However, it is thought that T2DM may create a favourable 
environment for cancer initiation and progression (42). The best investigated potential 
mechanisms explaining a link between the two diseases include: hyperglycaemia, chronic 
inflammation and hyperinsulinemia.  
1.5.3. Hyperglyceamia  
Hyperglycaemia is a key feature of T2DM (75). High levels of circulating glucose, which occurs 
as a result of hyperglycaemia, may facilitate tumour cell energetics and promote chronic 
proliferation (75). Tumour cells use glucose as a preferential source of energy, therefore, a 
glucose abundant environment may create advantageous conditions for tumour growth (75). 
Moreover, high glucose levels benefit tumour cell resistance to chemotherapy and reduce 
chemotherapy survival rates (82). Hyperglycaemia has been shown to increase the toxicity of 
chemotherapeutic drugs such as carboplatin and 5-fluorouracil by in vitro studies (82). In 
addition, according to a systematic review and meta-analysis performed by Alenzi et al. 
hyperinsulinemia increases the risk of chemotherapy induced neutropenia (CIN) by 32% (83). 
CIN is a condition which results in the reduction in neutrophil numbers leading to increased 
risk of developing infections by cancer patients undergoing chemotherapy (84). This may also 
contribute to the increased cancer specific mortality rates occurring in people with T2DM.  
1.5.4. Chronic inflammation  
Another factor which may benefit neoplastic processes in people with T2DM is fat induced 
chronic inflammation (85). T2DM and related obesity results in adipocytes producing abnormal 
levels of various inflammatory factors such as tumour necrosis factor-α (TNFα), interleukin-6 
(IL-6), plasminogen activator inhibitor-1 (PAI-1), monocyte chemoattractant protein, as well as 
adiponectin and leptin (85). Some of these changes in the levels of inflammatory factors are 
known to promote cancer development. For example, elevated expression of serine protease 
inhibitor PAL-1 has been shown to promote progression of several cancers including: breast, 
colorectal, endometrial, renal and thyroid cancers (85). Increased expression of the pro-
inflammatory cytokine TNF-α activates nuclear factor κβ (NFκβ), which upregulates expression 
of anti-apoptotic proteins and results in increased cell survival (86). Elevated serum levels of 
TNF-α have been reported to correspond with increased cancer-related death (85).    
1.5.5. Hyperinsulinemia  
Hyperinsulinemia is a term used to describe abnormally high insulin levels in the blood (87). 
Insulin is a hormone which regulates blood sugar levels by inducing glucose uptake into the 
cells and acts as a growth factor signalling to cells to proliferate (88). Insulin stimulation 
activates numerous biological pathways with many functions including growth, proliferation and 
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cell survival (88). Therefore, it is thought that chronic exposure to high levels of insulin may 
promote tumour growth (85). The stimulating effect of insulin on tumour cell proliferation was 
first reported in animal studies (89). In 1972, Heuson et.al showed that insulin promotes growth 
of mammary tumours induced by carcinogen (7,12‐dimethylbenz(a)anthracene) treatment in 
artificially insulin deficient rats (89).  
Epidemiological data shows that hyperinsulinemia increases the risk of colorectal (90) and 
endometrial (91) cancers. Moreover, it has been shown that it is an independent risk factor for 
breast cancer development in post-menopausal women (92). Hyperinsulinemia is very likely to 
explain the association between T2DM and cancer. It is a very early symptom of the disorder, 
usually developing before diagnosis (75). Therefore, it may be linked to the fact that the 
increase in incidence of cancers like colorectal, endometrium or breast occur within months 
after T2DM onset (93).  
In addition, high levels of insulin enhance hepatic production of insulin growth factor (IGF-1) 
(85). High concentrations of IGF-1 has been also associated with increased risk of cancer 
development (85). Some studies reported that IGF-1 has stronger mitogenic and anti-apoptotic 
effects on cells than insulin itself (85).  
The importance of hyperinsulinemia as a factor increasing risk of cancer in people with T2DM 
is supported by studies on metformin (94). Metformin is a drug used to treat T2DM, which 
increases tissue sensitivity to insulin and in this way reduces hyperinsulinemia (95). There is 
increasing evidence that people treated with metformin have lower risk of developing cancers 
than people treated with insulin or insulin analogues (94).  
 
1.6. Diabetes and colorectal cancer  
According to epidemiological data, people with T2DM have a 50% increased risk of developing 
colorectal cancer. In addition, T2DM increases the risk of dying from colorectal cancer by ~12% 
compared to people without diabetes (96). The connection between T2DM and colorectal 
cancer has been acknowledged by the American Diabetes Association (ADA) (97). According 
to the guidelines of the association, people with T2DM should be advised to change unhealthy 
lifestyle habits which increase cancer risk as well as undergo cancer screening befitting their 
age and sex (97).  
An association between T2DM and more aggressive colorectal tumours has been reported by 
some studies (98). The results of a retrospective analysis performed by Sharma et.al show 
that people with diabetes and colorectal cancer exhibit deeper tumour invasion and greater 
lymphovascular invasion than people without diabetes (98). In addition, the same study has 
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also indicated that people with diabetes have higher TNM (tumour node metastasis) staging 
and are more likely to develop transverse tumours (98).  
1.6.1. Hyperinsulinemia and colorectal cancer  
The impact of insulin on colorectal cancer has been examined by many in vitro and in vivo 
studies. For example, research performed by Tran el al. investigated the effect of various 
markers of insulin resistance on colorectal cancer in rats (99). The factors they examined 
included: hyperinsulinemia, elevated blood levels of glucose, fatty acids and triglycerides (99). 
The results of this study showed that hyperinsulinemia alone is able to increase proliferation 
of colorectal epithelial cells (99). The infusion of insulin in rats for 10 hours increased growth 
of colorectal epithelial cells in dose dependent manner (99). Similar results were obtained in 
an animal study performed by Corpet et al., where experimental rats were given either saline 
injections or ultralente bovine insulin injections (100). Data obtained from their investigation 
indicated that insulin promotes growth of aberrant crypt foci in the colon in rat models (100). 
Another example of a study investigating effects on insulin exposure on colorectal cancer 
phenotype was performed by Lu et.al. (101) The results of this investigation show that insulin 
stimulation promotes proliferation and migration of human colon cancer cell line - HCT-116 
(101). They showed that insulin promotes cancer development by increasing activity of the 
PI3K/Akt and MAPK signalling pathways. Furthermore, a study carried out by Liu et al. showed 
that hyperinsulinaemia may be a factor promoting angiogenesis in colorectal cancer (102).  
A study performed by Keku et al. also indicated an important role of hyperinsulinemia in 
colorectal tumour development (103). In their investigation, tissue samples from colonoscopy 
patients were collected in order to assess the relationship between plasma insulin, physiologic 
apoptosis and adenoma risk (103). The results of this study showed that high levels of 
circulating insulin positively correlate with increased adenoma risk. In addition, they found that 
elevated levels of circulating insulin may promote early adenoma progression by inhibiting 
apoptosis in normal colonic mucosa (103). Decreased levels of apoptosis caused by insulin 
stimulation may lead to accumulation of mutated cells, which may promote colorectal tumour 
development (103). Another study involving human subjects was carried out by Ortiz et al. In 
this study blood samples were collected from colonoscopy participants (104). In this study, 
researchers concluded that insulin resistance is a risk factor for the development of early stage 
colorectal tumours (104).    
1.7. Insulin signalling in insulin responsive tissues 
In the insulin responsive tissues, insulin signalling starts with the hormone binding to the insulin 
receptor (IR) on the cell surface. Upon insulin binding, the IR undergoes autophosphorylation 
on tyrosine residues, what leads to the recruitment of insulin receptor substrates (IRS) (88). 
The IR binds and phosphorylates IRS on tyrosine residues present within SH2 and PTB 
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domains. Phosphorylated IRS are able to bind and activate effector proteins including PI3K. 
Activated PI3K triggers conversion of membrane phospholipid - phosphatidylinositol (4,5)-
bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) (29). PIP3 recruits PH 
domain containing proteins such as Akt (88). Akt mediates the metabolic and mitogenic effects 
of insulin through downstream signalling (105).  
To exert a proliferative effect on cells, the PI3K/Akt pathway activates mTORC1 (105). 
mTORC1 induces cell growth by increasing the level of anabolic processes within the cell (32). 
For instance, it activates SREBP1, which mediates lipid synthesis and regulates mRNA 
translation via S6 kinase and 4EBPs (105). Furthermore, in order to release cells from cell 
cycle arrest, Akt mediates deactivation of the transcription factor FOXO, which subsequently 
gets degraded via the proteasome (105). In addition, Akt inhibits apoptosis by deactivating the 
pro-apoptotic protein – BAD (105). In order to push cells into S phase of the cell cycle, Akt 
phosphorylates GSK3, what results in the increase of cyclin D levels (105).  
With regards to the metabolic response to insulin stimulation, in muscle and adipose tissue, 
Akt drives the translocation of GLUT4 to the plasma membrane in order to facilitate glucose 
uptake (106). Moreover, Akt downregulates GSK3, which is an inhibitor of glycogen synthesis 
and lipogenesis (107). As a result, there is an increase in glucose uptake into cells, and any 
excess glucose is converted into glycogen (106).  
Besides activating the PI3K/Akt pathway, insulin binding to the IR also triggers the MAPK 
pathway. Activated IR and IRS recruit SH2 binding proteins such as Grb2 and Shc. Grb2 binds 
to proline rich-regions of son-of-sevenless (SOS) protein. SOS acts as a guanine nucleotide 
exchange factor for Ras. SOS activates Ras by catalysing a switch from GDP-bound Ras to 
GTP-bound Ras. Activated Ras triggers a downstream kinase cascade resulting in cellular 
proliferation.   
In addition, insulin has been shown to upregulate the pentose phosphate pathway as well as 
an uptake of glutamine and fatty acids into the cell (42). Increase in these anabolic pathways 






Figure 7. Insulin signalling pathways. Insulin binds to the insulin receptor (IR), which 
phosphorylates insulin receptor substrates (IRS). IRS recruit Shc and Grb, which activate SOS 
and drives MAPK signalling pathway. IRS also recruits PI3K, which triggers PIP2 conversion 
to PIP3 and Akt activation follows. Akt inhibits GSK3, FOXO and BAD and activates mTORC1. 
In addition, Akt triggers translocation of GLUT4 to the plasma membrane.  
 
1.8. Insulin and cancer metabolism  
The impact of insulin on cancer cell proliferation through its effects on cellular signalling has 
been extensively studied (as described earlier in this chapter). However, the effect of insulin 
on cancer cell metabolism has not been extensively explored. Some studies, which 
investigated the impact of insulin on cancer metabolism are discussed below:     
1.8.1.1. Insulin and HIF1α 
It has been shown that hyperinsulinemia induces HIF1α expression during normoxia in several 
cancers (108–110). As discussed above, HIF1α expression promotes the Warburg effect. 
HIf1α acts as a positive regulator of PDK1 (111) and LDH (112). Moreover, HIF1α also 
increases transcription of glucose transporters such as GLUT1 and in this way increases the 
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uptake of glucose to cells (113). In addition, HIF1α up-regulates transcription of PKM2, which 
also contributes to increased levels of glycolysis in cancer cells (114). In this way insulin may 
promote the Warburg effect in tumour cells. 
1.8.1.2. Insulin and PKM2 
In 2013, Iqbal et al. demonstrated that insulin stimulation up-regulates expression of the 
glycolytic enzyme PKM2 via the PI3K/mTOR pathway and concomitantly reduces it’s activity 
through an independent pathway in hepatocellular carcinoma cells. This rise in PKM2 
expression has been demonstrated to increase levels of glycolysis in cancer cells (114). Insulin 
induces the production of ROS which disrupt the tetrameric (most active) form of PKM2 and 
causes accumulation of its dimeric and monomeric structures (114). As a result, there is an 
increase in glucose uptake and a decrease in glycolytic flux, what leads to the accumulation 
of glycolytic intermediates and NADPH. The net outcome is upregulation of biosynthetic 
pathways in cancer cells (114).  
1.8.1.3. Insulin and G6PD 
There are also other ways by which hyperinsulinemia may stimulate biosynthetic pathways 
besides inducing aerobic glycolysis. Insulin is a known regulator of glucose-6-phosphate 
dehydrogenase (G6PD) expression (115). G6PD is an enzyme involved in initiating the 
pentose phosphate pathway. It is possible that chronic insulin exposure may upregulate the 
pentose phosphate pathway (PPP) in cancer cells (42). PPP results in lipid and nucleotide 
synthesis (116). Therefore, increased levels of PPP is beneficial for cancer cells as it provides 
building blocks necessary for chronic proliferation (116).   
1.8.1.4. Insulin and ASCT2 
Another aspect of cellular metabolism that insulin has been shown to influence is glutamine 
uptake (117). According to the protein atlas database, there is an increase in expression of the 
glutamine transporter - ASCT2 in colorectal cancer cells (118). Glutamine may be used by 









1.9. Aims and Objectives   
The aim of this project was to examine the impact of insulin exposure on colorectal tumour cell 
metabolism. Understanding the impact and mechanism of insulin action on colorectal tumour 
cell phenotype will help us to understand how T2DM promotes colorectal cancer development. 
In addition, better understanding of the specific molecular mechanisms by which insulin 
reprogrammes colorectal tumour cell metabolism may contribute to the development of new 
targets for cancer therapy. The specific aims of this study are:  
• To determine what stages of colorectal tumour development are the most sensitive to 
insulin stimulation. 
• To examine what signalling pathways are affected in sensitive cells lines.  






Chapter 2: Methods & Materials  
 
2.1. Tissue culture 
 
2.1.1. Cell lines  
In this study various human colorectal adenoma and carcinoma cells were used as in vitro 
models:  
2.1.1.1. HT29 
HT29 cell line was isolated from a sporadic colorectal adenocarcinoma (120). This cell line has 
mutations in APC (121), BRAF and TP53 (122) genes.  
2.1.1.2. SW480 
SW480 cell line was derived from a patient with colorectal adenocarcinoma (123). SW480 
harbour mutations in APC (121), KRAS and TP53 (122) genes.   
2.1.1.3. S/RG  
S/RG is a clonogenic cell line derived from a human tubular adenoma. This cell line has 
mutations in TP53. In addition, most of S/RG cells have one normal copy of chromosomes 
number 6, 7, 14, 17, 18, and 22 (124).  
2.1.1.4. AA cell line series  
The AA cell line series was established by progressive transformation of an adenoma cell line 
to a malignant carcinoma cell line using carcinogens (125). This cell line series was isolated 
and developed by the Williams’ group before I started my work in the laboratory (125). It was 
derived from a single large adenoma of 3-4cm in diameter from a patient with Familial 
Adenomatous Polyposis (FAP). The first cell line isolated (AA) was diploid, fibroblast feeder 
dependent and non-tumourigenic. Four cell lines were subsequently and sequentially 
generated from AA: AA/C1, AA/C1/SB, AA/C1/SB/10C, AA/C1/SB/10C/M (125). It is these four 
cell lines that I used in this project. 
Cells were transformed in a following order:  
AA/C1 represents the earliest stage of tumourigenesis. AA/C1 cells were isolated from AA after 
50 passages. AA/C1 was aneuploid, clonogenic and fibroblast feeder independent with some 
evidence of tumour progression in vitro. AA/C1 were treated with sodium butyrate for 14 days 
and this gave rise to AA/C1/SB. AA/C1/SB cells had 6.13% increased colony forming efficiency 
but remained anchorage dependent and non-tumouigenic. Next, AA/C1/SB cells were exposed 
to N-methyl-N’-nitro-N-nitrosoguanidine and this gave rise to AA/C1/SB/10C, which had 17.3% 
increased colony forming efficiency. They were also anchorage independent and became 
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tumourigenic in nude mice. AA/C1/SB/10C/M was derived from a tumour produced by 
inoculation of AA/C1/SB/10C in to nude mice (6).  
All AA series cell lines are aneuploid. They all carry one or two copies of abnormal 
chromosome 1 as well as one or two copies of normal chromosome 1. Abnormal chromosome 
1 is characterized by a pericentic inversion at bands p32 and q23 and loss of a fragment of 
short arm distal to band p32.  In addition, they show monosomy of chromosome 18 and carry 
up to six copies of chromosome 6,9 and 13. The original paper by Paraskeva et al. stated that 
abnormalities in chromosome 1 and multiple copies of chromosome 13 present in those cells 
may be important in colorectal tumour development and progression (126).    
 
 
Figure 8. Progression of AA cell line series. AA/C1 represents the earliest stage of 
colorectal tumourigenesis. It is clonogenic and anchorage dependent, but not tumorigenic. 
AA/C1/SB is a subsequent stage, still anchorage dependent and non-tumorigenic. 
AA/C1/SB/10C is an anchorage independent cell line. AA/C1/SB/10C/M is anchorage 
independent and tumorigenic in nude mice.  
2.1.2. Cell maintenance  
Dulbecco’s Modified Eagles Medium (DMEM, Sigma-Aldrich) cell growth media was used for 
all cell culture. HT29 and SW480 cell lines were cultured in DMEM supplemented with 10% 
(v/v) foetal bovine serum (FBS, Life technologies, Paisley, UK), 2mM L-glutamine, 100 units/ml 
penicillin (Life Technologies, Paisley, UK) and 100μg/ml streptomycin (Life Technologies, 
Paisley, UK). The AA cell line series and S/RG cell line were cultured in DMEM supplemented 
with 20% (v/v) FBS, 4mM L-glutamine, hydrocortisone (1μg/ml), 100 units/ml penicillin (Life 
Technologies, Paisley, UK), 100μg/ml streptomycin (Life Technologies, Paisley, UK) and 0.2 
units/ml insulin (Sigma, Poole, UK). Cell lines were cultured in 25cm3 (T25) flasks (Corning 
Incorporated, Corning, New York, USA) in a non-humidified incubator at 37˚C with 5% CO2. 
Growth media was changed every 3-4 days. 
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2.1.3. Cell passaging  
Cell lines were routinely passaged with the following frequency and split ratio: HT29 and 
SW480 – every 7 to 10 days with split ratio 1:10, S/RG – every 2 weeks with split ratio 1:4,  
AA/C1 – every 3 to 4 weeks with split ratio 1:4, AA/C1/SB – every 2 to 3 weeks with split ratio 
1:6, AA/C1/SB/10C – every 2 to 3 weeks with split ratio 1:8-1:10,  AA/C1/SB/10C/M – every 
10 to 14 days with split ratio 1:8 – 1:10.  
Cells were washed two times with 3ml of phosphate buffered saline (PBS, pH 7.4; Severn 
Biotech Ltd, Kidderminster, UK) and subsequently incubated with 1ml of 0.1% (w/v) trypsin 
solution (BD Bioscience, Oxford, UK) and 0.1% (w/v) ethylene-diamine-tetra-acetic acid 
(EDTA) (Sigma, Poole, UK). When cells detached from the plastic, media was added to the 
flasks to neutralize the trypsin. For HT29 and SW480 cell lines, the cell suspension was 
transferred into a universal and spun at 3000rpm for 3 minutes. Next, the liquid was aspirated 
off and the pellet was resuspended in 10ml of fresh media and used to seed new flasks. For 
the AA cell line series and S/RG cell line, cell suspension was mixed by pipetting up and down 
several times and directly transferred to new flasks.  
2.1.4. Cell counting  
Cells were counted using a 0.1mm Neubauer haemocytometer. Trypsinized cells were 
resuspended in media. 20ɥl of cell suspension was mixed with 20μl of trypan blue dye (Gibco® 
Life Technologies, USA) in order to distinguish live and dead cells. Next, the mixture was 
loaded on haemocytometer and counted either manually or by using the Corning Cell Counter 
(CytoSMART, Netherlands).  
2.1.5. Freezing down and recovery of cells   
To freeze down, cells were trypsinized and resuspended in DMEM with 10% 
dimethylsulphoxide (DMSO). Next, 1ml of cell suspension was transferred into a 1.2ml 
Cryovial® (Simport, Saint-Mathieu-de-Beloeil, Canada). Cryovials were placed in a Mr 
Frosty™ Freezing Container (Life Technologies, Paisley, UK) and kept in a -80˚C freezer for 
four hours. Subsequently, cryovials with cells were transferred into a -174˚C liquid nitrogen 
container.  
To bring up, 1ml of cell suspension from the cryovial was transferred into T25 flask and 3ml of 






2.2. Crystal violet cell viability assay  
2.2.1. Seeding cells  
Cells were seeded in 96 well plates with seeding density 6000 – 40 000 cells per well in 100μl, 
depending on the cell line. Cells were seeded in the 60 wells in the middle of the plate 
(excluding the outer wells). 200μl of PBS was added into the surrounding, outer wells in order 
to prevent evaporation of media. The growth media used for cell seeding was the same as that 
used for routine cell culture for each particular cell line. Plates were stored in a non-humidified 
incubator at 37˚C and 5% CO2.  
2.2.2. Treatment  
24 hours after seeding, growth media was aspirated off the plates and replaced with treatment 
media (this varies depending on the experiment and cell line). For the AA series, DMEM with 
10% FBS, 2mM glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin was used for 
experiments. For HT29 and SW480, DMEM with 2mM glutamine, 100units/ml penicillin and 
100 μg/ml streptomycin (supplemented with 4% FBS and with either 25mM or 3mM glucose 
(10% D-(+)-Glucose solution, Sigma Aldrich, UK) was used. In addition, treatment media 
contained various concentrations of a particular treatment agent. Plates were stored in a non-
humidified incubator at 37˚C and 5% CO2 until fixing. Treatment agents included: insulin or an 
AKT1/2 kinase inhibitor (Sigma, Poole, UK) prepared in DMSO (VWR International Ltd., 
Lutterworth, UK). For concentrations of treatments used see figure legends.  
2.2.3. Fixing  
Growth media was aspirated off the plates and 100μl of cold 4% paraformaldehyde (PFA) was 
added into each well with cells and five control wells containing just PBS. Plates were left for 
30 minutes to allow fixing of cells. Next, PFA was removed and 200μl of PBS was added to 
each well. Plates were covered with cling film and stored at 4˚C until staining.   
2.2.4. Staining  
PBS was aspirated off the plates. 100μl of 0.5% crystal violet stain (Sigma) was added to each 
well with cells and the five control wells without cells. Plates were placed on the rocker for 30 
minutes. Next, crystal violet stain was removed using a multichannel pipette and plates were 
rinsed with water. Plates were left to dry overnight.  
2.2.5. Solubilisation and absorbance measurement   
100μl of 2% SDS solution was added into each well. Plates were placed on a rocker for 1 hour. 
Next, the absorbance was measured at 595nm wavelength using the iMark™ Microplate 




2.3. Western Blotting  
 
2.3.1. Cell lysis  
Firstly, 1.5X cell lysis buffer (Cell Signalling Technology) was made. It was prepared out of 
10X cell lysis buffer by mixing 20mM Tris-HCl pH 7.5, 1% v/v Triton-X100, 150mM NaCl, 1mM 
EDTA 1mM β-glycerophosphate, 2.5M sodium pyrophosphate and 1mM sodium 
orthovanadate and diluting in ddH2O with Roche Complete Mini Protease Inhibitor tablet 
dissolved in 10ml. Growth media was aspirated off the flasks and cells were washed twice with 
2ml of ice cold PBS. 100ul of 1.5X cell lysis buffer was added to the flasks. Flasks were placed 
on ice and incubated on a rocker for 10 minutes. Subsequently, cells were scraped and 
transferred into a chilled Eppendorf tube. Next, the lysates were spun in the centrifuge at 
18500g at 1˚C for 10 minutes. After spinning supernatant was collected and transferred into 
an ice cold Eppendorf tube. Cell lysates were stored in -80˚C.   
2.3.2. Protein assay and sample preparation  
A blank (water) sample and the bovine serum albumin (BSA) protein standards with following 
concentrations: 6.25, 12.5, 25, 50, 100, 200, 400, 800 μg/ml were prepared.   
31ul of each standard and water control was added in duplicate to 96 well plate. Next, 1ul of 
each lysate and 30ul of ddH2O were added to a 96 well plate in triplicate. Subsequently, Bio-
Rad Protein assay reagents (Bio-Rad, CA, USA) were added to protein standards and samples 
in quantities stated in the manufacturer’s protocol in order to determine protein concentration 
in each sample. Absorbance was read at 750nm wavelength using the iMark™ Microplate 
Absorbance Reader (Bio-Rad, CA, USA). 
Samples were prepared with concentrations of 15-30μg/ml per 15μl and 5ɥl of 5X Laemmli 
sample buffer per 25μl of sample was added. Samples were boiled for 5 minutes, spun and 
stored at -20˚C.  
2.3.3. SDS-PAGE  
Polyacrylamide gels were prepared using Mini-Protean 3 Electrophoresis equipment (Bio-Rad, 
Hemel Hempstead, UK). Compositions and concentrations of gels are presented in the tables. 
15μl of each sample was loaded on a gel alongside 5μl the Precision Plus Protein™ Dual 
Colour Standard markers (Bio-Rad Laboratories Ltd., Watford, UK). The gel was run at 100V 
for 15 minutes and then at 180V for 60 minutes in running buffer (Table 1) until the samples 
reached the end of a gel.  
2.3.4. Transfer  
The glass cassette was disassembled, and the gel was pre-soaked in transfer buffer for 5 
minutes. Immobilon® polyvinylidene difluoride (PVDF) membrane was pre-soaked in 
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methanol, washed with ddH2O and soaked in transfer buffer. Next, a transfer cassette was 
assembled in a following order: sponge, two pieces of filter papers, acrylamide gel, 
Immunobilon membrane, two pieces of filter paper and sponge. The transfer was run using a 
Transblot Cell (Bio-Rad, Hemel Hampstead,  UK) at 100V for 1.5 hour.  
2.3.5. Blocking and protein detection    
When the transfer was finished, the membrane was incubated in blocking buffer (5% milk in 
TBST) on a rocker for 1 hour. Next, the primary antibody was prepared and diluted in 0.5% 
milk in TBST. The membrane was placed in a plastic bag and incubated with a primary 
antibody overnight at 4˚C. On the next day, the membrane was washed in TBST for 15 minutes 
three times. The secondary antibody was prepared by diluting an appropriate volume of the 
antibody in 0.5% milk in TBST. Membrane was incubated in secondary antibodies for 1 hour 
at room temperature. Next, the membrane was washed three times in TBST. Each wash lasted 
15 minutes. After the last wash, the membrane was rinsed in ddH2O. Detection of proteins was 
performed using LumiGLO Peroxidase Chemiluminescence Substrate (KPL, Maryland, USA) 
according to manufacturer’s protocol. Subsequently, the membrane was placed in a cassette 
on a stack of three x-ray films. Films were developed using a Compact X4 Film Processor and 
scanned using SilverFast® Ai Studio 9 software (Lasersoft Imaging AG). 
Table 1. Compositions of buffers used for western blotting. 




192mM Glycine National Diagnostics, 
Hessle, UK 
25mM Tris National Diagnostics, 
Hessle, UK 
0.1% (w/v) SDS Sigma, Gillingham, UK 
Transfer Buffer 192mM Glycine National Diagnostics, 
Hessle, UK 
25mM Tris National Diagnostics, 
Hessle, UK 
20% (w/v) methanol Sigma, Gillingham, UK 
Tris-Buffered saline - 
Tween 20 (TBST) 
50mM Tris, HCl pH 7.4 National Diagnostics, UK 
150mM sodium chloride BDH, VWR, Poole, UK 






Table 2. Reagents used to prepare acrylamide gels and their source.  



















































































Table 3. List of antibodies used in western blotting.  



































































































































Secondary  Anti-Mouse IgG 
Peroxidase 
Goat  1:1000 Sigma, Gillingham, 
UK 
Secondary  Anti-Rabbit IgG  
Peroxidase 





2.4.  Stable isotope tracer analysis  
Cells were seeded in 60mm/15mm plates (Corning®, USA) in 3ml of growth media. Seeding 
density used for AA/C1 was 4.5×106 cells per plate, whereas seeding density for 
AA/C1/SB/10C/M was 0.5×106 cells per plate. After 72h cells were treated with or without 
50ng/ml insulin for a further 72h. 
Next, media was prepared for stable isotope incubation. Glucose-free or glutamine free DMEM 
(Thermo Fisher Scientific, Paisley, UK)  was supplemented with 10% dialysed foetal bovine 
serum (dFBS) and either 10mM uniformly labelled 13C-glucose (U-[13C]-glucose) or 2mM 13C-
glutamine (U-[13C]-glutamine) respectively (Cambridge Isotope Laboratories Inc., USA). Before 
incubation, media was aspirated off and cells were washed with 2.5ml PBS. Media containing 
stable isotope tracers was added to plates with or without 50ng/ml insulin. Plates were 
incubated in tracer containing media for 2 hours.  
After 2 hours of incubation, media was aspirated off the plates and cells were washed with 2ml 
of ice-cold 9g/L saline solution. 800μl of ice-cold 80% methanol was added onto the plates. 
Plates were immediately placed on dry ice to stop cellular metabolism. Cells were scraped and 
transferred to pre-cooled Eppendorf tubes. A parallel set of plates was trypsinized and the cells 
were counted in order to normalize the data to cell number after analysis.   
Cellular debris were cleared from metabolomics samples by centrifugation at 21,000 x g at 4˚C 
for 10min and subsequently dried by vacuum centrifuge (Concentrator 5301, Eppendorf) (≤ 
4˚C, 18-24h). At this stage samples were sent to the Metabolomics Core Facility at McGill 
University, Montreal for analysis. Members of the Metabolomics Core Facility at McGill 
University carried out further preparation of the samples and ran them on the mass 
spectrometer, the data was returned and my supervisor, Dr Emma Vincent carried out the 
analysis. The data was then returned to me for presentation.  
Although I did not carry out the below, I have briefly described how the samples were prepared 
for mass spectrometry and analysed, this was adapted from (127) and further detail can be 
found in this reference: 
Cell pellets were dried and then resuspended in 30µl of pyridine with 10mg/ml methoxyamine 
hydrochloride (Sigma). Next, cell pellets were vortexed and sonicated. That was done in order 
to ensure pellet dissolution. Subsequently, 1µl of internal standard, myristic acid-D27 was 
dissolved in 750ng/µl of pyridine and added to the samples. Then, samples were moved to 
sealed autoinjection vials. Vials were heated at 70˚C for 30 minutes. After heating, 70µl of N-
tert-Butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) (Sigma) was added into the 
samples. Samples were incubated at 70˚C for 1 hour.  
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GC/MS analysis was carried out by using an Agilent 5975C GC/MS, which was containing a 
DB-5MS+DG (30m x 250µm x 0.25µm) capillary column (Agilent J&W, Santa Clara, CA, USA). 
Electron impact set at 70 eV was used to collect the data. 1µl of the derivatized sample was 
added through injection in the GC in splitless mode. The inlet temperature was at 280˚C.  
Helium was used as a carrier gas. A flow rate of 1.5512ml per min was used. This is a rate at 
which myristic acid elutes at 17.94min. The quadrupole temperature was set to 150˚C, whereas 
the GC/MS interface was set to 285˚C. The oven was programmed to start with 60˚C for 1 min. 
Then, the temperature in the oven was increasing for 10˚C per min until achieving 320˚C. 
Samples were kept at 320˚C for 10 minutes. Metabolites used in this investigation were 
validated in the past using authentic standards (all standards from Sigma) in order to confirm 
the mass spectra as well as the retention times.  
Agilent ChemStation software was used to integrate ion intensities. Stable isotope tracer 
analysis was acquired by mass isotopomer distribution analysis using an algorithm, which was 
created by the Metabolomics Core Facility at McGill adapted from (128). This algorithm was 
used in order to produce matrices correcting for natural abundance of 13C isotopomer in every 
metabolite. These matrices were then subtracted from each metabolite. The integrated ion 
intensities for each metabolite were normalised. Normalization was done by dividing the values 
obtained from the algorithm by the integrated ion intensities of the internal standard (myristic 
acid D27). Finally, the obtained values were divided by the mean number of cells, which was 
determined from parallel culture plates grown at the same time as the plates used in the 
experiment.  
 
2.5. Quantitative real time PCR (qPCR) 
2.5.1. Insulin treatment  
Cells were seeded in 60 mm/15 mm plates in 3ml of 20% DMEM and grown for 72 hours. 
Subsequently, media was aspirated off the plates and replaced with 10% DMEM either with or 
without 50ng/ml of insulin. Plates were stored in the incubator.  
2.5.2. RNA extraction  
After 72 hours, plates were washed two times with 2ml of PBS and 1ml of TRI reagent (Sigma, 
Gillingham, UK) was added onto the plates. Next, cells were extracted by scraping and 
transferring them into an Eppendorf tube. Subsequently 200μl of chloroform (BDH, VWR, 
Poole UK) was added into the Eppendorf tubes. After incubating for 5 minutes at room 
temperature, samples were centrifuged at 11 500rpm for 15 minutes at 4˚C. This resulted in 
samples separating into three layers. The top layer was collected and transferred into a clean 
Eppendorf tube. 500μl of isopropanol (BDH, VWR, Poole UK) was added, samples were 
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shaken and left for 10 minutes at room temperature. Subsequently, the samples were 
centrifuged at 11 500rpm for 10 minutes at 4˚C. The supernatant was disposed of and 1ml of 
70% ethanol was added into the pellet. Samples were spun at 8 500rpm for 5 minutes at 4˚C. 
Again, the supernatant was disposed of and the pellet was left for 5 minutes to air-dry. 100μl 
of molecular grade water was added and extracts were stored at -70˚C until proceeding to the 
washing steps.  
2.5.3.  Washing  
Qiagen RNeasy Mini kit (Qiagen, Manchester, UK) was used for RNA purification. 350μl of 
RLT buffer and 250μl of 100% ethanol was added to the Eppenforf tubes. Samples were mixed 
by pipetting and transferred into RNeasy mini spin column placed in a 2ml collection tube. 
Columns were centrifuged at 10 000 rpm for 1 minute. Next, a mix of 10μl of DNase and 70μl 
of RDD buffer was prepared and added to each column. Columns were left at room 
temperature for 15 minutes. Subsequently, 350μl of RW1 buffer was added to the columns 
and they were centrifuged again at 10 000rpm for 1 minute. Next, 500μl of RPE buffer was 
added and columns were centrifuged at 10 000 rpm for 1 minute. This step was repeated, 
however, the second time columns were centrifuged for 2 minutes. Column was placed in 1.5ml 
Eppendorf tube, 50μl of water was added to the columns. Columns were spun at 13 000rpm 
for 1 minute. After centrifuging samples were left at room temperature for 30 minutes. Next, 
the samples were kept on ice for 1 hour.  
2.5.4. Nanodroping and cDNA preparation  
A nanodrop spectrophotometer (Thermo Scientific, Karlsruhe, Germany) was used to 
determine RNA concentrations. 1.5μl of molecular grade water was used to calibrate the 
machine. Next, 1.5μl of each sample was loaded onto the machine and RNA concentration 
was measured.  
2ɥg RNA was added to a pair of PCR tubes. Next, 0.5µg Oligo dT primer (Promega, 
Southampton, UK) was added to the RNA. The PCR tubes were heated at 70°C for 5 minutes 
in order to allow annealing of the primer. After heating, the PCR tubes were placed on ice to 
avoid degeneration of secondary structures. Next, 5µl of 5x M-MLV reaction buffer (Promega, 
Southampton, UK) was added to each tube along with 5µl DeoxyribonucleotideTriphosphate 
(dNTPs) (10mM stock) (Promega, Southampton, UK) and 25 units of Recombinant RNasin 
Ribonuclease Inhibitor (Promega, Southampton, UK). In addition, 200 units of M-MLV reverse 
transcriptase enzyme was added to one PCR tube of the pair. The second PCR tube of the 
pair was a negative control with no enzyme added, hence no cDNA should be produced. 
Molecular grade water was added to the samples, so their final volume is equal to 25ɥl each. 
The PCR tubes were heated at 40˚C for one hour to allow cDNA synthesis. Later on, 75ɥl of 
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molecular grade water was added to each PCR tube, so the final concentration of cDNA 
produced was 20 ng/ɥl. cDNA was stored at -20˚C.  
2.5.5. Running a plate  
2ɥl of each cDNA sample was added into 96 well PCR plate (Agilent Technologies, West 
Lothian, UK) in triplicate. In addition, the negative control was added to a single well for each 
cDNA sample. Next, a master mix was prepared containing: 0.37 µl of forward and reverse 
primer, 6.25µl SYBR Green PCR Mix (Qiagen, Manchester, UK) and 3.5ɥl of molecular grade 
water for each sample. Plates were covered with strip lids and spun at 1,000rpm for 2 minutes. 
After spinning plates were placed in an MxPro 3005P Real-time Thermal Cycler (Agilent 
Technologies, West Lothian, UK) and analysed. In all experiments, a housekeeping gene; 














HIF1α TATGAGCCAGAAGAACTTTTAGGC CACCTCTTTTGGCAAGCATCCTG 
PDK1 CGGATCAGAACCGACACA ACTGAACCATTCTGGCTGGTGA 
PKM1 ACCGCAAGCTGTTTGAAGAA TCCATGAGGTCTGTGGAGTG 
PKM2 GAGGCCTCCTTCAAGTGCT CCGACTTGGTGAGAGACGAT 
MPC1 TGACCTTTGCTTTGTGTTGC CACCTTGGATCAATTGTGCT 






Chapter 3: Investigating the impact of insulin exposure on cell 
lines representing different stages of colorectal tumourigenesis  
 
3.1. Introduction  
As described in Chapter 1, hyperinsulinemia has been linked to increased risk of colorectal 
cancer development. However, it is unclear what stage of colorectal tumourigenesis is the most 
sensitive to insulin stimulation. Insulin has been shown to promote colorectal tumour cell 
proliferation by many in vitro studies (85,101,114,129,130). However, the majority of these 
studies use cell lines representing one stage of colorectal tumourigenesis (commonly 
adenocarcinoma). In this project I had the rare opportunity to test the effects of insulin on a cell 
line series modelling progressive transformation and representing the different stages of 
colorectal tumourigenesis. Therefore, I could observe the effects of insulin on colorectal cells 
at different stages of tumourigenesis. In addition, many of the studies to date have used supra-
physiological concentrations of insulin. In this investigation I used lower doses of insulin 
compared to other studies. In this way I could observe the effect of insulin on colorectal cells 
in conditions more similar to the physiological environment. It is important to explore the impact 
of insulin on colorectal cancer development in order to better understand why people with 
T2DM have an increased risk of colorectal cancer.  
The aim of this chapter was to assess what stages of colorectal tumourigenesis are most 
sensitive to insulin stimulation. Tumour cell proliferation in response to insulin was assessed 
by a crystal violet based cellular proliferation assay. This was performed on cell lines 
representing different stages of colorectal tumour progression. In addition, cellular 
responsiveness to insulin was examined by performing western blotting to assess the extent 
of Akt phosphorylation. Later in this Chapter, the impact of insulin on cellular signalling was 
further analysed by assessing the expression of various insulin signalling pathway 
components. To assess whether Akt signalling was responsible for mediating the impact of 
insulin on cell proliferation, the cell line most sensitive to insulin stimulation was treated with 









3.2. The impact of insulin on the proliferation of adenocarcinoma cells 
 
3.2.1. Optimisation of the proliferation assay for adenocarcinoma cell lines  
I first examined the effect of insulin treatment on the proliferation of two colorectal 
adenocarcinoma cell lines – HT29 and SW480. These cell lines represent the later stages of 
tumourigenesis. Before I attempted to assess the effect of insulin on the proliferative response 
of these cells, I performed an optimization experiment to determine which serum concentration 
to use in the assay. The aim of this experiment was to determine the minimum serum 
concentration that permits cell proliferation, which would also enable me to observe an effect 
of insulin above the normal level of proliferation. Previous experience in the laboratory has 
shown that these cell lines struggle to survive in serum free conditions for longer than 48 hours. 
HT29 cells were grown in 96 well plates with media containing various serum concentrations. 
Subsequently, the proliferative response of cells in each condition was measured (Figure 9). 
The results of this experiment indicate that the optimum serum concentration, which allows 
HT29 cells to proliferate is 4%. The result of this experiment is presented in Figure 9.  
 
 
Figure 9. Proliferative response of HT29 when treated with media containing various 
concentrations of serum. Cells were seeded in 96 well plates (6000 cells per well) in growth 
media containing following concentrations of serum: 0%, 0.5%, 1%, 2%, 4%, 8%. Plates were 
fixed after 24, 48, 96 and 168 hours and stained using crystal violet. Error bars represent 






3.2.2.  The effect of insulin on the proliferation of HT29 and SW480 cell lines  
After establishing the optimal conditions for the crystal violet assay for colorectal 
adenocarcinoma cell lines, the proliferative response of HT29 and SW480 was measured in 
response to insulin dosing. The results of this experiment show that insulin significantly 
increased proliferation of HT29 after 24 hours of treatment. All concentrations of insulin used 
in the experiment significantly increased proliferation of HT29 at this timepoint. Increase in the 
number of viable cells occurred in a dose dependent manner. At the later timepoints (48h, 72h 
and 96h) insulin did not have any positive effect on proliferation of HT29 cells. After 72h and 
96h of insulin stimulation the number of treated cells decreased compared to control. In 
contrast to HT29, SW480 did not respond to insulin proliferatively after 24 hours. The only 
significant increase in proliferation of SW480 cells was observed when cells were treated with 
50ng/ml insulin for 48 hours. After that timepoint, SW480 cells did not show increased or 
decreased proliferation in response to insulin treatment. Taken together these data suggest 
that proliferation of these adenocarcinoma cell lines is not sensitive to insulin.  


























Figure 10. The effect of insulin adenocarcinoma cell proliferation. HT-29 and SW480 cells 
were seeded in 96 well plates in growth media. After 24 hours of incubation, media was 
changed to media with 4% FBS and cells were treated with various concentrations of insulin 
(0,10, 50, 100 and 1000 ng/ml). Plates were fixed after 0, 24, 48, and 96 hours and proliferation 
was analysed by crystal violet staining. The line graphs represent all the data from the 
experiment. The bar graphs indicate proliferation of cells at each time point: either 24, 48, 72 
and 96 hours of insulin exposure. Error bars represent standard deviation from one experiment 
with 5 technical replicates (n=5). Data were analysed by one-way Anova and Dunnett’s test of 
multiple comparisons. Statistically significant values are indicated (using a p value threshold 
of p = 0.05). Significance indicated in asterisk (*), where: * means p ≤ 0.05, ** means p ≤ 0.01, 
*** means p ≤ 0.001.   
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3.2.3. The effect of insulin on cellular signalling in adenocarcinoma cells  
Given that insulin did not increase proliferation of the adenocarcinoma cells, I next decided to 
examine whether insulin incubation stimulated cellular signalling in these cells. Western 
blotting analysis was performed to assess activation of Akt, as measured by phosphorylation 
at serine 473, upon insulin stimulation (Figure 11). The results of this experiment show that 
HT-29 cells respond to insulin exposure at lower timepoints (2h, 4h, 6h), however, this effect 
is not sustained at higher timepoints (24h, 48h). The level of phospho-Akt induction is greatest 
after 2 hours of treatment and decreases over time. In addition, the basal level of phospho-Akt 
rises after 48 hours in non-treated cells.  
 
Figure 11. The effects of insulin treatment on Akt signalling in adenocarcinoma cells. 
HT-29 cells were treated with insulin (100ng/ml) for 2, 4, 6, 24 and 48 hours. Cell lysates were 
collected at each timepoint and immunoblotting analysis was performed for total and phospho-
Akt (S473). Tubulin was used as a loading control.  
 
 
3.3. The effect of insulin on the different stages of colorectal tumourigenesis  
 
3.3.1. The effect of insulin on proliferation of the cell line series modelling adenoma to 
adenocarcinoma tumour progression.  
As insulin treatment did not affect the proliferation of colorectal adenocarcinoma cells, 
representing late stage disease, I decided to test whether it influences the proliferative 
response of cells representing earlier stages of tumourigenesis. To do this I used a cell line 
series representing an in vitro model of tumour progression – an adenoma to carcinoma 
sequence of the same lineage. This model consists of four cell lines, which progress from early 
adenoma to carcinoma as follows:  AA/C1 (anchorage dependent and nontumourigenic), 
AA/C1/SB, AA/C1/SB/10C and AA/C1/SB/10C/M (anchorage independent and tumourigenic). 
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The proliferation of each cell line was examined in both the presence and absence of insulin 
(Figure 12).  
Data obtained from this experiment indicate that the cell line representing the earliest stage of 
adenoma progression – AA/C1, was the most sensitive to insulin treatment. All concentrations 
of insulin used in this assay, except of the lowest (1ng/ml), significantly increased proliferation 
of this cell line at the latest timepoint and did so in a dose dependent manner. The higher 
insulin concentrations – 50ng/ml, 100ng/ml and 1000ng/ml also significantly increased 
proliferation of AA/C1 cells after 72 hours. The proliferative effect of insulin on this cell line 
magnifies as time progresses. After 120 and 168 hours 10ng/ml insulin also significantly 
increased proliferation of AA/C1. Although there is no significant effect detected when these 
cells are stimulated with 1ng/ml of insulin, the p value obtained from one way Anova is equal 
to 0.7.  
The proliferative response to insulin on the successive AA series cell lines decreases as the 
series progresses. There was no significant change observed in the proliferation of AA/C1/SB, 








Figure 12. Proliferative response of an adenoma derived cell line series following 
incubation with insulin. Cells were seeded in 96 well plates in growth media. After 72 hours 
of incubation, media was changed to experiment media with various concentrations of insulin 
(0, 10, 50, 100 and 1000 ng/ml). Plates were fixed after 0, 72, 120 and 168 hours and 
proliferation was analysed by crystal violet staining. Line graphs on the top row are 
representative data from one experimental repeat (the graphs for the other experiments 
performed are in the appendix). The bar graphs in the rows below represent averaged data 
across experimental repeats for each individual time point; 72, 120 and 168 hours of insulin 
exposure respectively. Error bars represent SEM for three separate experiments for AA/C1, 
two experiments for AA/C1/SB and AA/C1/SB/10C and one experiment for AA/C1/SB/10C/M. 
All individual experiments have 5 technical replicates (n=5). Data were analysed by one-way 
Anova and Dunnett’s test of multiple comparisons. Statistically significant values are indicated 
(using a p value threshold of p = 0.05). Significance indicated by asterisk (*), where: * means 





3.3.2. The effect of insulin on the proliferation of the adenoma to adenocarcinoma 
cell line series following long term insulin withdrawal.  
Insulin is used in the routine cell culture of the AA series cells. This may affect the cellular 
sensitivity to insulin that we observe in the assay (Figure 12). It may also mean that rather than 
testing cellular response to insulin I was more likely testing cellular response to insulin 
withdrawal. Therefore, I decided to repeat the proliferation assays for the AA cell line series 
following long term insulin withdrawal (1 month for all cell lines with the exception of AA/C1 
which was withdrawn from insulin for 5 days). Crystal violet proliferation assays were 
performed to assess whether there were any changes in proliferation of cells after they were 
re-stimulated with insulin following long term withdrawal. Data obtained from this experiment 
show that insulin treatment increases proliferation of AA/C1 and AA/C1/SB the most 
significantly. The change in AA/C1/SB/10C proliferation is only significant when cells are 
treated with the highest concentration of insulin. The results also show a decrease in 
proliferation of AA/C1/SB/10C/M when treated with insulin. Although AA/C1/SB and 
AA/C1/SB/10C cell lines became more sensitive to insulin treatment after long term insulin 
withdrawal, the overall pattern of insulin sensitivity of this cell line series remains similar. Insulin 
increases proliferation of cell lines representing the early stages of colorectal tumour 
progression, but does not stimulate proliferation in cellular models of the later stages of tumour 












































Figure 13. Proliferative response of the adenoma cell line series following insulin 
withdrawal and re-stimulation. Cells were grown in insulin free conditions for one month 
(AA/C1/SB, AA/C1/SB/10C, AA/C1/SB/10C/M) or 5 days (AA/C1). Next, cells were seeded in 
96 well plates in growth media. After 72 hours of incubation, media was changed to experiment 
media with various concentrations of insulin (0,10, 50, 100 and 1000 ng/ml). Plates were fixed 
after 0, 72, 120 and 168 hours. The line graphs represent all the data from the experiment. 
The bar graphs indicate proliferation of cells at each time point: either 72, 120 and 168 hours 
of insulin exposure. Error bars represent SD from one experiment with 5 technical replicates 
(n=5). Data were analysed by one-way Anova and Dunnett’s test of multiple comparisons. 
Statistically significant values are indicated (using a p value threshold of p = 0.05). Significance 








3.3.3. The effect of insulin on cellular signalling in adenoma cells. 
Next, to determine the effect of insulin on cellular signalling, induction of Akt activity was 
determined for each cell line. The results of western blotting analysis indicate that the cell line 
representing the earliest stage of tumour progression was the most responsive to insulin 
stimulation. There is a visible increase in phosphorylation of Akt at S473 after 2 h of insulin 
stimulation in AA/C1. Moreover, this level of phospho-Akt expression is sustained after 24 
hours of treatment in this cell line. Although insulin appears to trigger the greatest induction of 
phospho-Akt expression in AA/C1, it also exerts an effect on the other cell lines. There is a 
visible increase in phospho-Akt induction in AA/C1/SB and AA/C1/SB/10C/M after 10 minutes, 
2 hours and 24 hours of treatment. The induction of phospho-Akt in AA/C1/SB/10C is the least 
affected by insulin stimulation. The level of phospho-Akt slightly increases in this cell line after 
10 minutes and 2 hours of treatment, however, it falls after 24 hours. It is worth mentioning that 
the basal level of phospho-Akt expression is noticeably higher in all three cell lines, when 
compared to AA/C1. Overall, the results of western blotting analysis indicate that all of the 
examined cell lines are responsive to insulin, however, AA/C1 appears to be the most sensitive 
(Figure 14).  
 
Figure 14. The effects of insulin treatment on Akt signalling in colorectal adenoma cell 
lines. Cells were treated with insulin (100ng/ml) for 10 minutes, 2 hours and 24 hours. Cell 
lysates were collected at each timepoint and immunoblotting analysis for total and phospho-
Akt (s473) was performed. Tubulin was used as a loading control. A replicate of this 





Subsequently, I decided to further explore the ways cellular signalling induced by insulin 
differed between the four cell lines. I performed western blotting analysis to detect any changes 
in expression levels of phospho-Akt, insulin growth factor receptor β, insulin receptor and the 
Akt substrate phospho-PRAS40 (131). This analysis was performed to compare expression 
levels of the above proteins in cells treated with and without insulin (100ng/ml) for 72 hours.  
Consistent with Figure 15 the results of this experiment showed that after 72 hours of 
treatment, insulin has the greatest effect on phospho-Akt induction in the AA/C1 cell line. In 
addition, insulin stimulation increased induction of phospho-Akt in AA/C1/SB and 
AA/C1/SB/10C cell lines. Interestingly, there is no phospho-Akt induction upon insulin 
treatment in the AA/C1/SB/10C/M cell line. This is consistent with the failure of this cell line to 
respond to insulin in the proliferation assay. We can observe a similar pattern of expression in 
the Akt target protein – phospho-PRAS40 (131). Insulin increases induction of phospho-
PRAS40 in AA/C1/SB and AA/C1/SB/10C cell lines, but it does not trigger any phospho-
PRAS40 induction in AA/C1/SB/10C/M cell line. However, insulin induces only a very small 
increase in expression of phospho-PRAS40 in the AA/C1 cell line, this is inconsistent with the 
phospho-Akt result. Furthermore, AA/C1 is the only cell line which shows decreased 
expression levels of the insulin receptor and IGFRβ upon insulin stimulation.  
 
 
Figure 15. The effects of insulin treatment on insulin signalling in colorectal adenoma 
cell lines. Cell were treated with insulin (100ng/ml) for 72 hours. Cell lysates were collected 
and immunoblotting analysis for total and phospho-Akt (s473), IGFRβ, phospho-PRAS40 and 




After observing that insulin was able to sustain activation of the Akt signalling pathway for 72 
hours in cell lines representing early, but not late stages of colorectal tumourigenesis I decided 
to examine the proliferative response of the AA/C1 cell line when treated with insulin and 
incubated with an Akt inhibitor. That was done in order to test whether the proliferative 
response to insulin was dependent on Akt activation. In this experiment I performed the crystal 
violet proliferation assay to compare the proliferation of cells when treated with different 
concentrations of an Akt inhibitor with or without insulin. I performed two experiments, first with 
a lower range of Akt inhibitor concentrations (Experiment 1: 0-10μM) then with a higher range 
(Experiment 2: 0-20μM). The results of both experiments (Figure 16) show that the proliferative 
effect of insulin on the AA/C1 cell line is inhibited to a large extend when cells are treated with 
10, 15 and 20μM of Akt inhibitor. However, the Akt inhibitor also inhibits proliferation of cells 
when they are untreated with insulin. Despite this, the fold decrease in proliferation when 
comparing Akt inhibitor treated cells to control is greater for insulin treated cells than for the 
non-insulin treated cells. For example, in Experiment 1 at 168h the average fold decrease in 
proliferation with 20μM of Akt inhibitor in 2.54 fold in non-insulin treated cells vs 3.75 fold in 
insulin treated cells. There was no difference in cell proliferation when cells where treated with 















Figure 16. Proliferative response of AA/C1 to insulin following treatment with an Akt 
inhibitor. Cells were seeded in 96 well plates in growth media. After 72 hours of incubation, 
media was changed to experiment media and cells were treated with various concentrations 
of Akt inhibitor. Concentrations used in Experiment 1 were to 0, 0.5, 1, 2, 5 and 10ɥM, whereas 
concentrations used in Experiment 2 were to 0, 2, 5, 10, 15 and 20ɥM. Each condition was 
repeated with the addition of 50ng/ml of insulin. Plates were fixed after 0, 72, 120 and 168 
hours. Crystal violet staining was performed to measure proliferation. Data were normalized to 
control without insulin or Akt inhibitor. Multiple t-tests were performed between control and 
cells treated with Akt inhibitor and between control and cell treated with Akt inhibitor plus 
insulin. Statistically significant values are indicated (using a p value threshold of p = 0.05). 
Significance indicated in asterisk (*), where: * means p ≤ 0.05, ** means p ≤ 0.01, *** means p 





Next, I performed western blotting analysis to assess the level of phospho-Akt induction in 
AA/C1 cells treated with 50ng/ml of insulin and various concentrations of Akt inhibitor. The Akt 
inhibitor doses used in this experiment were in the same range as used for the proliferation 
assay (Figure 17). The results of this analysis show that cells stimulated with insulin express 
phospho-Akt and this is ablated by the addition of any concentration of Akt inhibitor used.   
 
Figure 17. The effects of insulin treatment on levels Akt signalling in the AA/C1 cell line. 
Cell were treated with various concentrations of Akt inhibitor (0, 2, 5, 10, 20 ɥM), with or without 
50ng/ml of insulin for 72 hours. Cell lysates were collected and immunoblotting analysis for 
total and phospho-Akt (s473) was performed. Tubulin was used as a loading control.  
 
In my next experiment I examined the effect of insulin on proliferation of another cell line 
representing early stage of colorectal tumour progression – S/RG (Figure 17). I did this with 
the aim to replicate my findings in the AA/C1 cell line. I carried out the crystal violet proliferation 
assay using the same conditions as for the AA/C1 cell line, to determine whether insulin 
promotes proliferation of early adenoma cells in different models. The results of this experiment 
show that insulin increases proliferation of the S/RG cell line. Insulin dosed at 50 ng/ml, 100 
ng/ml and 1000 ng/ml significantly increases proliferation of S/RG cell line after 72h of 
treatment. After 120h, the highest concentration of insulin still significantly increases 
proliferation of this cell line. After 168h, insulin dosed at each concentration, except of 1ng/ml, 
significantly increases proliferation of S/RG cell line. The effects of insulin are similar to those 
observed in AA/C1 cell line. However, the S/RG cells seem to be more sensitive to higher 
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concentrations of insulin. There is a large increase in proliferation of this cell line upon 
stimulation with 1000ng/ml compared to 100ng/ml. This effect was not observed in AA/C1 cell  
line.   
 
 
Figure 18. Proliferative response of the S/RG cell line following incubation with insulin. 
Cells were seeded (seeding density 20 000 cells/well) in 96 well plates in growth media. After 
72 hours of incubation, media was changed to experiment media and cells were treated with 
various concentrations of insulin (0,10, 50, 100 and 1000 ng/ml). Plates were fixed after 0, 72, 
120 and 168 hours and proliferation was analysed by crystal violet staining. The line graph 
displays all the data from this experiment. The bar graphs indicate proliferation of cells at the 
individual time points: 72, 120 and 168 hours of insulin exposure. Error bars represent SEM 
from one experiment with 5 technical replicates (n=5). Data were analysed by one-way Anova 
and Dunnett’s test of multiple comparisons. Statistically significant values are indicated (using 
49 
 
a p value threshold of p = 0.05). Significance indicated in asterisk (*), where: * means p ≤ 0.05, 




In this part of my investigation, I examined the impact of insulin exposure on colorectal 
adenoma and carcinoma cell proliferation. Proliferation assays were performed to assess 
which stage of colorectal tumour progression was the most sensitive to insulin. Data obtained 
from these experiments indicate that insulin increases proliferation of early adenoma cells – 
AA/C1 the most significantly. The proliferative effect of insulin was absent in subsequent 
adenoma stages AA/C1/SB, AA/C1/SB/10C and AA/C1/SB/10C/M. In order to confirm my 
finding that early adenoma cells are the most sensitive to insulin treatment, the proliferation 
assay was repeated using a different adenoma cell line - S/RG. This cell line also represents 
the early adenoma stage of colorectal tumourigenesis.  
After long term insulin withdrawal, all cell lines became more sensitive to insulin treatment. 
There was a significant increase in proliferation of AA/C1/SB and also AA/C1/SB/10C. 
However, sensitivity of the cell line series to insulin was still most apparent in the models of 
the early stages of colorectal tumorigenesis. In addition, there was no increase in proliferation 
of adenocarcinoma cell lines – HT29 and SW480 upon insulin stimulation. Hence, I determined 
that the early stages of colorectal tumour progression are the most sensitive to the effects of 
insulin. 
The lack of a proliferative effect of insulin on cell line models representing the later stages of 
colorectal tumourigenesis may be connected to an increase in the number of oncogenic 
mutations carried by these cells. Progressive accumulation of mutations observed in cancer 
cells may make them less reliant on exogenous growth factors such as insulin. The results of 
western blotting analysis for phospho-Akt showed that the greatest level of phospho-Akt 
induction is apparent in the cell line model of an early adenoma (AA/C1) upon insulin treatment 
in comparison to models representing the later stages of colorectal tumourigenesis. Moreover, 
phospho-Akt induction was sustained in AA/C1 after 72 hours. In contrast, there was no 
phospho-Akt induction visible in cell line models representing the later stages of colorectal 
tumourigenesis after 72 hours. These results may be explained by the presence of additional 
mutations downstream of Akt in cell lines representing the later stages of colorectal 
tumourigenesis. Another explanation of this phenomena could be that late stage colorectal 
tumour cells decrease their dependency on the Akt pathway for tumorigenicity. It has been 
found by Vasudevan et.al that some cancer cells with a mutation in PIK3CA and low pAkt 
induction become dependent on SGK3 for viability (132). The kinase domain of SGK3 shares 
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a high level of homology with the Akt kinase domain, therefore it can be activated in PIK3CA 
mutant cancer cells via PDK1 dependent phosphorylation. They showed that mutations in PI3K 
may affect PDK1 positioning on the cell membrane and hence the affinity for Akt/SGK3 proteins 
(132).  
Differences in phospho-Akt activation between cell lines may also be a result of increased 
expression of AMPK in later stages of colorectal tumour. It has been shown in other cancers 
that as cells become more metastatic the levels of AMPK expression increases (133). Saha 
et. al has found that in breast cancer cells AMPK is able to upregulate protein phosphatase 2A 
(PP2A), which dephosphorylates and inactivates Akt. In this way AMPK drives cellular 
adaptation to matrix detachment (133).  
The results from my western blotting and proliferation assay experiments suggest a critical role 
for Akt signalling in the proliferative response to insulin in the early adenoma cell line, AA/C1. 
Using an Akt inhibitor in the proliferation assay demonstrated that phospho-Akt induction in 
AA/C1 in response to insulin is a potential reason for the increased proliferation observed in 
this cell line.   
Western blotting analysis in the adenocarcinoma cell line – HT29 indicated an increase in 
phospho-Akt induction at lower timepoints – 10 minutes and 2 hours, however, this was not 
sustained after 24 and 48 hours of treatment. Taking into consideration that the cell cycle takes 
around 24 hours to complete, this may explain why there was no effect on proliferation in these 
cells after insulin treatment. In addition, lack of phospho-Akt induction at later timepoints in the 
HT29 cell line may suggest that later stages of colorectal tumourigenesis do not rely on growth 
factors to activate Akt signalling pathway target proteins.  
According to my results, insulin treatment did not exert any effect on proliferation of colorectal 
adenocarcinoma cells. This contradicts the evidence in the literature, in which several studies 
state that insulin increases the proliferation of colorectal carcinoma cell (129,134,135). For 
example, Ayiomamitis et al. shows that insulin treatment induces proliferation of CaCo2 and 
HT29 cell lines (135). However, these studies use assays that measure reducing equivalent 
such as MTT and CCK8 as a way to measure cellular proliferation (135). Reducing equivalent 
assays measure the metabolic activity of cells and make the assumption that this correlates to 
the number of viable cells (136). In MTT assays, tetrazolium salt is reduced by mitochondrial 
and extra-mitochondrial dehydrogenases, this results in the formation of insoluble blue 
formazan crystals, which when solubilised indicate the number of viable cells (136). In contrast 
to the MTT assay, in the CCK8 assay a highly water soluble tetrazolium salt - WST-8, is 
reduced by dehydrogenases present in the plasma membrane and is combined with the 
electron acceptor PMS, which causes a change in media colour to yellow (136). These 
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methods of measuring proliferation may not be reliable in this type of investigation. Insulin is 
known to affect the metabolic activity of cells. Thus, insulin stimulation may induce changes in 
the levels of certain metabolites, without affecting proliferation rate (or not affecting it relative 
to cell number). In this investigation, the crystal violet cell viability assay was used to measure 
cellular proliferation. This method relies on the detection of biomass of viable cells, not their 
metabolic activity (137). Hence it is a more reliable way to assess cellular proliferation of insulin 
treated cells. In addition, many studies use supra-physiological concentrations of insulin, going 
up to about 2500ng/ml and not below 30ng/ml (101,129,135). Taking into consideration that 
maximum physiological concentration of insulin is about 10ng/ml, these conditions are very 
different from those found in humans. In this investigation I used insulin doses ranging from 
1ng/ml to 1000ng/ml, which encompass the physiological range.   
The adenoma to carcinoma cell line series used in these experiments has been derived from 
a patient diagnosed with familiar adenomatous poliposis (FAP) (125). Therefore, it may not be 
entirely representative of sporadic cancers, which constitute 90% of all colorectal cancer 
incidence (138). However, FAP patients have an APC mutation, which is present in the majority 
of sporadic colorectal cancers (139). Differences in genetic mutations present in various cell 
lines may affect tumour phenotype and responsiveness to growth factors. For example, it has 
been demonstrated that different types of APC mutations in colorectal tumours can influence 
tumour phenotype and prognosis (138). Therefore, it was important to carry out my analysis in 
different in vitro models.  
I used the S/RG adenoma cell line to replicate my findings in the AA/C1 cell line. This cell line 
is derived from a patient with sporadic cancer and in contrast to AA/C1 it expresses the full 
length APC (140). The results of proliferation assays performed with the S/RG cell line show 
similarity to those in the AA/C1 cell line. There was a significant increase in proliferation of 
S/RG cell line when stimulated with all concentrations of insulin used except 1ng/ml. These 
results suggest that it is the early stages of colorectal tumourigenesis which are the most 
sensitive to insulin. However, due to time restrictions this experiment was performed only once. 
Therefore, more research is needed to confirm these findings.     
 
3.5. Summary 
The results presented in this chapter show that cell lines representing the early adenoma stage 
of colorectal tumour progression are the most sensitive to insulin stimulation. However, this 
observation may not be true for all colorectal cell lines. As mentioned earlier in this chapter, 
each cell line has specific mutations and some of them may impact on the effect of insulin. 
Therefore, in the future, proliferation assays with other cell lines should be performed in order 
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to confirm these findings. The results of this investigation show that insulin does not increase 
the proliferation of late stage colorectal tumour cell lines. However, it may promote other 
properties of cancer cells. In the future, it will be worth exploring the effect of insulin on other 
phenotypes such as migration, invasion and angiogenesis.   
The results of proliferation assays show that it is not possible to entirely inhibit insulin 
stimulated growth with an Akt inhibitor in early stage cells. This suggests that insulin may 
promote proliferation of these cells through other pathways as well. In the next chapter, I will 
describe how insulin may increase proliferation of colorectal tumour cells through metabolic 




Chapter 4. The effect of insulin on metabolic reprogramming in 
colorectal tumour cells 
 
4.1.  Introduction 
Results described in the previous chapter show that insulin increases proliferation of early 
adenoma, but not adenocarcinoma cells. Although my results suggest that Akt signalling plays 
a role, the specific molecular mechanisms, by which insulin promotes proliferation of early 
adenoma cells remains unclear. In addition, the reasons behind insulin not affecting 
proliferation of adenocarcinoma cells are also unexplained. In order to proliferate tumour cells 
must reprogramme their intracellular metabolism to meet the demands of chronic proliferation. 
Therefore, I hypothesised that insulin might impact cell proliferation in the adenoma cells by 
promoting changes to cellular metabolism. I hypothesised that insulin may promote changes 
in the adenoma cells and not in the adenocarcinoma cells. Therefore, the aim of this chapter 
was to examine the effect of insulin on metabolic reprogramming in colorectal early adenoma 
and adenocarcinoma cells. In order to address this aim I have used stable isotope tracer 
analysis (SITA) and investigated my findings further using western blotting analysis and qPCR. 
The abundance of metabolites and metabolic flux was compared in insulin treated and non-
treated early adenoma and adenocarcinoma cells using SITA. Western blotting analysis was 
performed to examine whether insulin treatment affects the expression of various metabolic 
proteins and enzymes in early adenoma and adenocarcinoma cells. Data obtained from this 
experiment helped me determine some aspects of metabolism affected by insulin, such as 
aerobic glycolysis. Metabolic enzymes participating in glycolysis were further analysed by 
qPCR.  
 
4.1.1 Stable Isotopomer Tracer Analysis (SITA) 
Stable isotopomer tracer analysis (SITA) involves incubating cells with a stably labelled 
isotopomer (commonly glucose or glutamine) and quantifying the incorporation of the labelled 
carbon into cellular metabolites using mass spectrometry. Here, I am using uniformly labelled 
glucose (U-[13C]-glucose) and glutamine (U-[13C]-glutamine). The heavy labelled carbon can 
be distinguished from the unlabelled, naturally abundant carbon, due to the extra neutron on 
the 13C. Therefore, uniformly labelled glucose (U-[13C]-glucose), with 6 13C carbons is 6 mass 
units heavier than 12C glucose. This is referred to as m+6 glucose and the unlabelled, naturally 
abundant glucose as m+0 glucose.  
Glucose is metabolized down the glycolytic pathway into pyruvate, lactate and alanine. From 
uniformly labelled glucose (U-[13C]-glucose) fully labelled or m+3 pyruvate, lactate and alanine 
are produced (Figure 19). Glucose can also be converted from 3PG to generate the amino 
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acids serine and glycine. From uniformly labelled glucose m+3 serine and m+2 glycine would 
be produced. Pyruvate is oxidized and decarboxylated to generate m+2 acetyl-CoA and this 
enters the TCA cycle. Acetyl-CoA m+2 condenses with oxaloacetate to generate citrate, if the 
OAA is unlabelled as would be expected in the first turn of the TCA cycle it will produce m+2 
citrate. Citrate is decarboxylated to form m+2 α-ketoglutarate and the 2 labelled carbons 
continue around the TCA cycle until again OAA condenses with another m+2 acetyl-CoA to 
form m+4 citrate in the second turn of the TCA cycle. The cycle continues and the labelling 
patterns generated are demonstrated in Figure 20.   
The key advantage of SITA is that it allows you to assess both the relative abundance of 
metabolites and metabolic pathway activity by looking at how carbon is incorporated into 
different pathways. This is done by assessing the heavy labelled carbon labelling patterns of 
metabolites using mass isotopomer distribution (MID) analysis. This determines how many 
carbons are labelled from the tracer (in this case either glucose or glutamine). This analysis 
breaks the whole metabolite pool (equal to 1) down to asses which mass isotopalogues the 
pool is composed of. For example, for lactate, which has 3 carbons, the pool is composed of 
either unlabelled lactate (denoted m+0), lactate labelled at one carbon (m+1), lactate labelled 
at two carbons (m+2) or lactate labelled at three carbons (m+3). As mentioned above, because 
of how U-[13C]-glucose is metabolised by glycolysis into lactate, the majority of the lactate 
produced will be the m+3 mass isotopalogues (there will be very little m+1 and m+2 
contributing to the MID for lactate). Shifts in the proportions of mass isotopalogues can indicate 
altered metabolic pathway flux and tell us about what metabolic pathways are engaged or 
prioritised in different conditions. 
Uniformly labelled glutamine (U-[13C]-glutamine) has 5 13C carbons and is therefore 5 mass 
units heavier than 12C glutamine. U-[13C]-glutamine is metabolised to m+5 glutamate and it 
enters the TCA cycle as m+5 α-KG, this process is called glutamine anaplerosis. Once in the 
TCA cycle, α-KG is metabolised in an either oxidative (clockwise to succinate) or reductive 
(anticlockwise to citrate) manner. The m+5 mass isotopalogue of citrate is indicative of 
reductive metabolism (conversion of α-KG to citrate). The m+4 mass isotopalogues of 




Figure 19. Labelling patterns for glycolysis and TCA cycle metabolites resulting from 
incubation of cells with uniformly labelled glucose (U-[13C]-glucose). U-[13C]-glucose 
(m+6) is taken up by cells and is metabolised to m+3 pyruvate, lactate and alanine. Pyruvate 
is decarboxylated and enters the TCA cycle as m+2 acetyl-CoA. This condenses with m+0 
oxaloacetate to give m+2 citrate. The TCA cycle progresses, maintaining the m+2 label until 
oxaloacetate again condenses with acety-CoA, giving m+4 citrate. This time a labelled CO2 is 
lost resulting in m+3 α-KG and the cycle continues. Figure adapted from: (141).  
 
4.2. The impact of insulin on metabolic flux in colorectal adenoma and 
adenocarcinoma cells.  
In order to examine the metabolic changes in colorectal tumour cells stimulated with insulin I 
performed SITA. In SITA 13C labelled nutrients (glucose or glutamine) are supplied to cells, 
upon extraction of the metabolites it is possible to measure the abundance and labelling 
patterns of metabolites (indicative of metabolic pathway usage) using GCMS. These data allow 
me to determine how the cell use key carbon sources and whether this changes when they 
are incubated with insulin.  
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In this investigation SITA was performed using AA/C1 and AA/C1/SB/10C/M cell lines. I 
decided to compare the model of early adenoma most impacted by insulin incubation (AA/C1) 
to the most progressed cell line in the series least impacted by insulin (AA/C1/SB/10C/M). I 
have used SITA to compare the incorporation of carbon from glucose and glutamine into the 
metabolites of two key cellular metabolic pathways: glycolysis and TCA cycle, in insulin treated 
and non-treated cells. In addition, the abundance of amino acids was also determined in the 
presence and absence of insulin treatment.  
4.2.1. SITA using uniformly labelled glucose (U-[13C]-glucose) 
In the first experiment, uniformly labelled 13C glucose (U-[13C]-glucose) was used as the tracer 
molecule. The tracer was supplied to cells 2 hours before to extraction. Cells were treated with 
insulin for the 72 hours before to extraction.  
I have grouped the metabolites according to the pathways they are in; glycolysis (Figure 20A), 
TCA cycle (Figure 20B) and amino acids (Figure 20C). Figure 20 shows the relative abundance 
of the metabolites in these pathways and indicates (by the black bars) how much labelled 
carbon from glucose has been incorporated into each metabolite. The results of U-[13C]-
glucose SITA showed a significant increase in the abundance of labelled lactate and alanine 
in the insulin stimulated AA/C1 cell line (p ≤ 0.01 for alanine, p ≤ 0.05 for lactate) (Figure 20A). 
In contrast, there was no change in the amount of labelled lactate and alanine in the 
AA/C1/SB/10C/M cell line in response to insulin. This suggests insulin might increase glycolytic 
activity in the AA/C1 cell line but not in the AA/C1/SB/10C/M. In addition, there was also an 
increase in the amount of unlabelled glycine (p ≤ 0.01) and serine (p ≤ 0.05) in the insulin 
treated AA/C1 cell line compared to control. There is little evidence of incorporation of labelled 
glucose into either serine or glycine, suggesting that AA/C1 and AA/C1/SB/10C/M do not use 
glucose to synthesise these amino acids and likely transport then into the cell from the culture 
media. 
Next I assessed the abundance of glucose carbon incorporated into the TCA cycle (Figure 
20B). The metabolic changes in response to insulin in the TCA cycle are less consistent. Insulin 
appears to increase carbon incorporation into some TCA cycle metabolites (malate, fumarate 
and α-ketoglutarate) upon insulin stimulation in both the AA/C1 and AA/C1/SB/10C/M cell 
lines.   
Next I assessed the relative abundance of amino acids in the cells. Amino acids are essential 
biosynthetic building blocks for proliferating cells. In several of the amino acids, insulin 
increased their intracellular abundance in the AA/C1 cells but not in the AA/C1/SB/10C/M cells. 
This was most obvious in the essential amino acids (isoleucine, leucine, valine, methionine 
and phenylalanine). This suggests insulin might increase amino acid uptake in the AA/C1 cells 
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but not in the AA/C1/SB/10C/M cells. This might help support the increase in cellular 
proliferation in the AA/C1 cells. In addition, the amount of unlabelled amino acids was much 
higher in AA/C1 cell line than in AA/C1/SB/10C/M cell line regardless of the presence or 
absence of insulin.  
I next further analysed cellular metabolism by considering the labelling patterns of the 
metabolites or the mass isotopomer distribution (MID). This determines how many carbons are 
labelled from the tracer (in this case glucose). This analysis breaks the whole metabolite pool 
(equal to 1) down to asses which mass isotopalogues the pool is composed of. As mentioned 
above, the majority of the lactate and alanine produced will be the m+3 mass isotopalogues. 
Figure 21A shows the MID for glycolysis metabolites. Consistent with no incorporation from 
glucose in serine and glycine (Figure 21A) the MID indicates mainly the m+0 mass 
isotopalogue for these amino acids. For alanine and lactate there is a decrease in m+0 and an 
increase in m+3 in response to insulin in both cell lines tested. This suggests insulin increases 
conversion of glucose into lactate and alanine in both cell lines.   
I next assessed the MID of the TCA cycle intermediates. Glucose carbon enters the TCA cycle 
most commonly as acetyl-CoA. This condenses with OAA to from citrate. See Section 4.1.1 
for more detail. Changes to TCA cycle metabolites are again quite inconsistent across cell 
lines and upon insulin stimulation (Figure 21B). Insulin appears to increase glucose conversion 
into citrate and α-ketoglutarate upon insulin stimulation in both cell lines (indicated by reduced 
m+0 in response to insulin). This is not apparent in other TCA cycle intermediates (except 
fumarate).  
4.2.2. SITA using uniformly labelled glutamine (U-[13C]-glutamine) 
Next, I performed another SITA in AA/C1 and AA/C1/SB/10C/M cell lines, but this time I used 
13C-glutamine (U-[13C]-glutamine) as the tracer molecule.  
As expected, I did not observe glutamine carbon in the glycolysis intermediates (Figure 22A). 
With regards to the total abundances of glycolytic metabolites, I observed the same results as 
in the glucose tracing SITA (Figure 20A). This demonstrates the reproducibility of this result.  
Glutamine SITA indicated that insulin treatment increases the abundance of some of the 
labelled TCA cycle intermediates (citrate, α-ketoglutarate, fumarate, malate and glutamate) in 
AA/C1 cell line but not in the AA/C1/SB/10C/M cells (Figure 22B). However, not all the total 
abundance results are replicated from the glucose experiment, therefore this experiment 
should be repeated before drawing too many conclusions.  
Similarly, to glucose tracing SITA, glutamine tracing SITA indicated an increase in the amount 
of unlabelled amino acids in insulin treated AA/C1 cell line compared to control. In addition, 
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there was an increase in the amount of labelled proline in AA/C1 cell line when treated with 
insulin. These results replicate the results observed in the glucose tracing SITA. 
I next further analysed glutamine metabolism by considering the MID of the TCA cycle 
intermediates (Figure 23). Glutamine is converted to glutamate and enters the TCA cycle as 
α-KG, this process is known as glutamine analplerosis (see section 4.1.1. for more detail). α-
KG is then metabolised in the TCA cycle in an either oxidative (to succinate) or reductive (to 
citrate) manner. The m+5 mass isotopalogue of citrate is indicative of reductive metabolism 
(conversion of α-KG to citrate), as this is low in both cell lines and unchanged by insulin 
stimulation I will focus only on oxidative metabolism here. The m+0 mass isotopalogue is 
decreased and the m+4 mass isotopalogue increased consistently in all TCA cycle 
intermediates in the AA/C1 cells in response to insulin. These are unchanged in response to 
insulin in the AA/C1/SB/10C/M cells. This suggests that the AA/C1 cells are increasing 





































Figure 20. The impact of insulin on intracellular metabolism. Stable isotope tracer 
analysis (SITA) with uniformly labelled 13C glucose (U-[13C]-glucose) was performed in 
AA/C1 and AA/C1/SB/10C/M cell lines. Relative abundance of the components of 
glycolysis (A), TCA cycle (B) and amino acids (C) was measured in insulin treated 
AA/C1 and AA/C1/SB/10C/M cell lines. Cells were seeded and treated with insulin 72h 
later. Cells were treated with insulin for 2h. Before extraction cells were incubated with 
13C glucose (U-[13C]-glucose) for 2h. Metabolite abundances are relative to myristic 
acid, the internal standard. The total abundance of each metabolite is shown as the 
total of 12C (white bars) and 13C (black bars). The schematics demonstrates the 
labelling of U-[13C]-glucose into the glycolytic (A) and TCA cycle (B) metabolites. 
Statistically significant values are indicated (using a p value threshold of p = 0.05). Significance 
indicated in asterisk (*), where: * means p ≤ 0.05, ** means p ≤ 0.01, *** means p ≤ 0.001.    
 
Figure 21. The impact of insulin on intracellular metabolism. Stable isotope tracer 
analysis (SITA) with uniformly labelled 13C glucose (U-[13C]-glucose) was performed in 
AA/C1 and AA/C1/SB/10C/M cell lines. A. The Mass isotopomer distribution (MID) 
pattern for the metabolites is presented for glycolysis (A) and the TCA cycle (B) in 
insulin treated AA/C1 and AA/C1/SB/10C/M cell lines. Cells were seeded and treated 
with insulin 72h later. Cells were treated with insulin for 2h. Before extraction cells were 
incubated with 13C glucose (U-[13C]-glucose) for 2h. The data are presented as a 
proportion of the total metabolites pool (equal to 1). The schematics demonstrates the 
labelling of U-[13C]-glucose into the glycolytic (A) and TCA cycle (B) metabolites. 
Statistically significant values are indicated (using a p value threshold of p = 0.05). Significance 
indicated in asterisk (*), where: * means p ≤ 0.05, ** means p ≤ 0.01, *** means p ≤ 0.001.    
 
Figure 22. The results of stable isotope tracer analysis (SITA) with uniformly 
labelled 13C glutamine (U-[13C]-glutamine). A. Relative abundance of the 
components of glycolysis was measured in insulin treated AA/C1 and 
AA/C1/SB/10C/M cell lines. B. Relative abundance of TCA cycle intermediates was 
measured in insulin treated AA/C1 and AA/C1/SB/10C/M cell lines. Statistically 
significant values are indicated (using a p value threshold of p = 0.05). Significance indicated 




Figure 23. The results of stable isotope tracer analysis (SITA) with uniformly 
labelled 13C glutamine (U-[13C]-glutamine). Mass isotopomer distribution of the 
components of glycolysis was measured in insulin treated AA/C1 and 
AA/C1/SB/10C/M cell lines. B. Mass isotopomer distribution of TCA cycle 
intermediates was measured in insulin treated AA/C1 and AA/C1/SB/10C/M cell lines. 
Statistically significant values are indicated (using a p value threshold of p = 0.05). Significance 






















4.3.  The impact of insulin on the expression levels of metabolic proteins and 
enzymes in the early adenoma and adenocarcinoma cells.  
After establishing that insulin treatment increases proliferation and changes metabolism in a 
model of early adenoma, I wanted to understand if insulin altered the expression of metabolic 
proteins and enzymes to support this. Western blotting analysis was performed to examine the 
levels of expression of various metabolic proteins and enzymes in AA/C1 cells in response to 
insulin stimulation (Figure 24). Results obtained from this analysis indicated some changes in 
metabolic proteins and enzymes following insulin treatment. A decrease in insulin receptor 
expression after 48 and 72 hours of treatment, indicated that the cells were responding to 
insulin. Because levels of essential amino acids were elevated in AA/C1 cells after insulin 
stimulation (Figure 24A) I wanted to test the expression of LAT1 (a branched chain amino acid 
transporter) in insulin treated cells. Unexpectedly, LAT1 expression decreased after 48 hours 
of treatment and was unchanged at 72h. Because I found that glutamine anaplerosis was 
increased in insulin treated AA/C1 cells (Figure 22A), I wanted to assess the expression of a 
glutamine transporter (ASCT2) and the enzyme that catalyses the first step in glutamine 
anaplerosis (GLS1). Expression of neither of these enzymes was changed by insulin 
stimulation. Because there is an increase in glycolysis metabolites in AA/C1 cells I wanted to 
test the expression of PDK1. Increased expression of PDK1 could lead to an increase in 
glycolysis, as it phosphorylates and inhibits PDH (see section 1.4.2.5. in introduction). I 














Figure 24. The impact of insulin on the expression levels of metabolic proteins and 
enzymes. A. Western blotting analysis was performed for insulin receptor (isoform β), LAT1, 
ASCT2 and GLS1. The experiment was carried out using the AA/C1 cell line. Cells were 
treated with 100 ng/ml of insulin for 48 and 72 hours. Tubulin was used as a loading control. 
B. Western blotting analysis was performed for pyruvate dehydrogenase kinase 1 (PDK1) in 
the AA/C1 cell line. Cells were treated with 100 ng/ml insulin for 48 and 72 hours.  
 
The elevated levels of PDK1 expression induced by insulin may provide an explanation for 
increased proliferation of early adenoma cells. Therefore, western blotting analysis was 
performed to compare the expression levels of PDK1 in the early adenoma cell line – AA/C1 
and adenocarcinoma cell line – AA/C1/SB/10C/M. The results indicated an increase in PDK1 
expression in both cell lines after 24 and 72 hours of insulin treatment (Figure 25). This 
therefore suggests that this metabolic response is not unique to the AA/C1 cells. To further 
analyse the changes in tumour cell metabolism, that happen particularly during pyruvate entry 
into TCA cycle, I performed western blotting analysis for MPC1. MPC1 transports pyruvate into 
the mitochondria for use in the TCA cycle. The levels of expression of MPC1 was analysed 
and compared in AA/C1 and AA/C1/SB/10C/M cell lines after 72 hours of insulin treatment. 
The results of this analysis showed that MPC1 expression is the same in insulin treated and 
non-treated AA/C1 cells. However, there was very little MPC1 expression detectable in both 



















Figure 25. The impact of insulin on the expression levels of PDK1 and MPC1. A. Western 
blotting analysis was performed to test PDK1 expression in AA/C1 and AA/C1/SB/10C/M cell 
lines. Both cell lines were treated with 100ng/ml of insulin for 24 hours. Tubulin was used as a 
loading control. The results indicated an increase in PDK1 expression in both cell lines in 
response to insulin. B. Western blotting analysis was performed to test the expression of PDK1 
and MPC1 in C1 and AA/C1/SB/10C/M cell lines. Both cell lines were treated with 50ng/ml of 
insulin for 72 hours. Tubulin was used as a loading control. The results indicated an increase 
in PDK1 expression in both cell lines in response to insulin. There was no change in the 
expression levels of MPC1 in AA/C1 cell line. The expression of MPC1 in AA/C1/SB/10C/M 
cell line is lost.  
 
 
4.4. The impact of insulin on the mRNA expression of glycolytic enzymes in 
colorectal adenoma and adenocarcinoma cells  
Western blotting analysis showed an increase in PDK1 expression in response to insulin in 





explore this pathway. qPCR was performed to analyse the mRNA expression levels of various 
enzymes involved in glycolysis, in response to insulin. This experiment was carried out for 
AA/C1 and AA/C1/SB/10C/M cell lines.  
Data obtained from qPCR showed that the mRNA expression levels of multiple enzymes 
increase when cells are treated with insulin. Insulin up-regulated HIF1α, PDK1, PKM1 and 
LDH mRNA expression in both cell lines tested. The insulin-induced increase in HIF1α mRNA 
expression was greater in the AA/C1/SB/10C/M cell line than in the AA/C1 cells. However, the 
size of error bars indicates high variability in this data. Therefore, this experiment should be 
repeated before conclusions are drawn.     
 
Figure 26. The impact of insulin on the mRNA expression of metabolic enzymes. qPCR 
was performed to test the mRNA expression levels of different metabolic enzymes: HIF1α, 
PDK1, PKM1, PKM2, LDHA in the AA/C1 cell line (A) and the AA/C1/SB/10C/M cell line (B). 





4.5. Discussion  
 
4.5.1. Insulin promotes Warburg effect in colorectal tumour cells   
SITA indicates that insulin increases glycolysis in the AA/C1 early adenoma cells. An increase 
in labelled lactate and alanine were detected in insulin treated early adenoma cells by SITA. 
The results of glucose MID analysis indicated a decrease in m+0 and an increase in m+3 
lactate and alanine in insulin treated AA/C1 and AA/C1/SB/10C/M cell lines. Suggesting both 
cell lines have an increased conversion rate of glucose to lactate and alanine upon insulin 
stimulation. Western blotting analysis also revealed that insulin stimulation increased PDK1 
expression levels in both early adenoma and adenocarcinoma cells. Due to the fact that PDK1 
inhibits pyruvate conversion to acetyl-CoA, elevated levels of this enzyme may promote a 
glycolytic phenotype in tumour cells. Under the conditions of high PDK1 expression, pyruvate 
entry to TCA cycle will be reduced, this will lead to elevated levels of lactate and alanine 
production. In this way insulin may promote Warburg effect in colorectal tumour cells.  
qPCR results showed an increase in LDHA and HIF1α mRNA levels upon insulin treatment in 
both cell lines. Elevated levels of LDHA mRNA may indicate an increase in pyruvate 
conversion to lactate confirming a shift towards aerobic glycolysis. A rise in HIF1α mRNA 
expression in insulin treated cells may explain an increase in PDK1 expression. HIF1α is 
known to regulate PDK1 expression (142) and also to be activated by insulin in some cell lines 
(108) (109). However, western blotting analysis and siRNA knockdown experiments should be 
performed in the future to confirm whether PDK1 activation is induced by HIF1α in the AA/C1 
and AA/C1/SB/10C/M cell lines used here.   
Inhibition of PDK1 may be a possible therapeutic target to counteract the Warburg effect in 
tumour cells. Some PDK1 inhibitors are already in clinical trials. For example, dichloroacetate 
(DCA), which was investigated as a possible treatment for type 2 diabetes (143). DCA 
modulates glucose and fat metabolism and has been investigated for its effects on cancer. It 
has been shown to increase pyruvate dehydrogenase (PDH) activity and decrease circulating 
lactate concentration upon oral administration (143). There are two possible mechanisms of 
DCA action. DCA may increase PDH activity by binding to its pyruvate binding pocket and 
blocking PDKs binding to its E2 domain. Another possible mechanism is that DCA triggers a 
conformational change in nucleotide and lipoamine binding sites, what leads to the inhibition 
of PDKs bindingc(143). However, its effectiveness on cancer and possible side effects on 




4.5.2. Insulin may promote other cancer hallmarks in colorectal adenocarcinoma cells 
through the activation of HIF1α 
Elevated levels of glycolysis and the resulting increase in biosynthetic reactions in insulin 
stimulated colorectal tumour cells may explain the increase in the proliferation of the AA/C1 
cell line when treated with the hormone. However, data obtained from western blotting analysis 
and qPCR suggests that both AA/C1 and AA/C1/SB/10C/M cell lines show very similar 
metabolic changes when treated with insulin. It may be possible that an activation of the same 
metabolic pathways promotes different phenotypes in early adenoma than in adenocarcinoma 
cells. Taking into consideration that there was very little expression of MPC1 protein in insulin 
treated and non-treated adenocarcinoma cells, it is likely that pyruvate entry to TCA cycle is 
already reduced at this stage of tumour progression (144,145). This is consistent with studies 
that have shown reduced expression of MPC1 is advances CRC (53,145). Therefore, the 
insulin stimulated increase in PDK1 expression may not have much effect on the level of 
glycolysis in AA/C1/SB/10C/M cell line.  
HIF1α activation may be increased by high lactate production in colorectal cells. It has been 
found by Wei et.al that high levels of lactic acid within cells may inhibit degradation of HIF1α 
under normoxic conditions in endothelial cells (146). This leads to an increase in vascular 
endothelial growth factor (VEGF) and promotion of angiogenesis (146). 
If insulin promotes metabolic reprogramming in colorectal tumour cells via activation of HIF1α, 
it is possible that multiple hallmarks of cancer cells may be promoted through this pathway 
simultaneously. The primary role of HIF1α in tumour cells is to provide adaptation to hypoxia 
(147). Hypoxia is a common event in more advanced solid tumours (148). It occurs when 
tumours outgrow the oxygen supply provided by the vasculature (148).  In the condition of 
oxygen deprivation, HIF1α drives numerous changes in cellular signalling in order to sustain 
tumour cell growth and proliferation (147). These adaptations triggered by HIF1α involve 
evasion of cell death by apoptosis and necrosis, promotion of migratory behaviour, 
angiogenesis and proliferation (147). As described in Chapter 1, HIF1α can be activated by 
insulin signalling (108) (109). It may be possible that insulin activated HIF1α provides 
adaptation to hypoxia in AA/C1/SB/10C/M cell line but does not have proliferation promoting 
effects in normoxia. This speculation may be examined by performing a proliferation assay in 
a hypoxic chamber to measure the viable cell number in response to insulin dosing and oxygen 
deprivation.   
HIFα is a potential target for cancer therapy. There are many studies investigating HIF1α 
inhibitors and their efficacy as anticancer drugs. It has been found that such drugs as digoxin 
(149) and acriflavine (150) are able to supress tumour growth through inhibiting HIF1α. 
Elevated levels of HIF1α has been shown to increase resistance to chemotherapy. Therefore, 
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HIF1α inhibitors have potential to be used as a component of combination anti-cancer 
therapies in the future (151).  
 
4.5.3. Insulin promotes glutamine anaplerosis in early adenoma cells  
Not all the changes to metabolism are happening in both the early, AA/C1 and late stage 
AA/C1/SB/10C/M cells. An increase in glutamine anaplerosis was observed only in the early 
adenoma cells. Although tumour cell metabolism is usually shifted towards glycolysis, the 
levels of the TCA cycle and oxidative phosphorylation are also often increased in tumour cells 
(152). However, because of the high levels of aerobic glycolysis, there is a limited amount of 
pyruvate entering mitochondria. Therefore, it is common for tumour cells to increase the usage 
of glutamine as a carbon source for the TCA cycle (65). This phenomena is known as 
anaplerosis (65). Data collected by SITA indicated a large increase in the amount of labelled 
glutamine, glutamate and α-KG in insulin treated AA/C1 cells compared to control. These 
results indicate that insulin increases anaplerosis in early adenoma cells. When glutamine is 
used by cells as a carbon source for the TCA cycle, it is first broken down to glutamate by an 
enzyme called GLS1 in a process called glutaminolysis (119). In the next step glutamate is 
converted into α-KG, an intermediate of TCA cycle (119). The increase in the flux of these 
metabolites in AA/C1 upon stimulation with insulin indicates that increased anaplerosis occurs. 
In contrast, there was no increase in the amounts of labelled glutamine, glutamate and α-KG 
in insulin stimulated adenocarcinoma cells compared to control. This result indicates that 
insulin affects glutamine metabolism in early adenoma cells, but not in adenocarcinoma cells. 
That may, at least partially, explain the increase proliferation of AA/C1 cells in response to 
insulin treatment. The amounts of TCA cycle intermediates, as well as glutamine and glutamate 
was generally higher in AA/C1/SB/10C/M cell line than in AA/C1. It is possible that 
adenocarcinoma cells already have mutations in some components of glutamine metabolism, 
hence insulin does not affect them as much.  
The results of glutamine MID analysis also support this speculation. The increased proportion 
of labelled carbons in response to insulin in TCA cycle intermediates (m+4 succinate, fumarate, 
malate and citrate) correlates with the hypothesis that increased anaplerosis in response to 
insulin occurs in early adenoma and not in adenocarcinoma cells.   
The expression levels of some proteins participating in glutamine metabolism were 
investigated by using western blotting analysis. For example, the levels of expression of 
glutamine transporter – ASCT2 was analysed in early adenoma and adenocarcinoma cells in 
response to insulin. The results of this experiment showed no difference in expression of the 
transporter. In addition, western blotting analysis was carried out to check the expression levels 
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of GLS1 in insulin treated and non-treated early adenoma cells. Again, there was no difference 
visible in the expression of this protein in response to insulin stimulation. Nonetheless, there 
are many more enzymes involved in glutamine metabolism, whose aberrant activation could 
cause increased anaplerosis in early adenoma cells. For example, there is another glutamine 
transporter called ATB0,+ , which mediates glutamine uptake into cells (153). ATB0,+ is 
expressed in  tissues at low levels, however, it has been found to be up-regulated in some 
breast cancers (153). Moreover, mutation in SLC6A14 – gene encoding ATB0,+  are studied for 
their association with X-linked obesity (154). It may be worth examining whether insulin affects 
the expression of this transporter. Insulin may also affect the activity of the transporters and 
enzymes involved in glutamine  anaplerosis without affecting their expression.  
Another mechanism, which may promote analperosis in colorectal tumour cells is caused by 
mutations in the PIK3CA gene(155). It has been shown in colorectal tumour cells that mutations 
in this gene increase expression of glutamate pyruvate transaminase 2 (GPT2), one of the 
enzymes that triggers glutamate conversion to α-KG (155). This results in tumour cells 
developing glutamine dependency (155). PI3K is a part of the insulin signalling pathway (156), 
so it is possible that insulin promotes glutamine anaplerosis via this mechanism. Western 
blotting analysis could be carried out for PI3K and GPT2 in order to test this hypothesis. In 
addition, qPCR could be performed to examine the mRNA expression levels of various 
components of glutamine metabolism in insulin treated AA/C1 and AA/C1/SB/10C/M cell lines.  
Glutamine metabolism is a potential target for cancer therapy. GLS, GDH and 
aminotransferase inhibitors are investigated for cancer treatment (66). However, most of the 
drugs are still in preclinical trials (66). There are many limitations of targeting glutamine 
metabolism. For example, glutamine anaplerosis can be driven by many different enzymes. 
Hence, inhibiting one class of enzymes would not prevent glutamine from supplying carbons 
into TCA cycle (66). A combination of many different inhibitors would be necessary. In addition, 
a lot of drugs investigated to target glutamine metabolism have been rejected due to high 
cytotoxicity (66).   
4.5.4. Insulin increases amino acids synthesis in early adenoma cells  
Data obtained from SITA showed an increase in the amount of various amino acids in insulin 
stimulated AA/C1 cells compared to control. This may be explained by the fact that insulin 
signalling activates mTORC1, which triggers amino acid synthesis (156). Interestingly, amino 
acids levels are less in the adenocarcinoma cells than in early adenoma cells. This may be 
because amino acid pools are depleted quicker in the more progressed, highly proliferative 
cells. Further research is needed to explore the reasons for the difference in amino acids 
abundance in colorectal tumour cells representing different stages of tumour progression.  
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4.5.4.1. Insulin increases BCAAs uptake in early adenoma cells  
Insulin increased the intracellular levels of essential amino acids in the early adenoma cells 
and not in the late stage cells. The insulin induced changes in the levels of the branched 
chained amino acids (BCAAs) are of particular interest. Elevated serum levels of BCAAs – 
leucine, isoleucine and valine have been associated with increased risk of developing T2DM 
by epidemiological studies (157). BCAAs metabolism is also an important aspect of metabolic 
reprogramming in cancer cells. They are used as biosynthetic intermediates and to generate 
ATP (158). They also activate mTORC1, and as a consequence drive protein synthesis, cell 
growth and survival (158). In addition, when BCAAs are catabolized, acetyl-CoA and succinyl 
CoA are produced, so additional sources of carbon for the TCA cycle are generated (158). 
Taking into consideration all of these properties, high levels of circulating BCAAs may support 
tumour cell proliferation and contribute to cancer development in people with T2DM.  
Data obtained from SITA showed an increase in the amount of BCAAs in insulin stimulated 
AA/C1 cells. Increased BCAA uptake stimulated by insulin may explain why AA/C1 cells 
proliferate more in response to insulin. BCAA intake is mediated by L-type amino acid 
transporter 1 (LAT1) (159). Western blotting analysis was performed for LAT1 in AA/C1 cell 
line stimulated with insulin for 48 and 72h. The results of this experiment indicated a decrease 
in the levels of LAT1 expression after 48 hours of insulin treatment. This result does not support 
the data showing an increase in the levels of BCAAs in insulin treated cells. In the future, 
western blotting analysis could be performed to analyse the expression levels of LAT1 in insulin 
treated AA/C1 cells at more timepoints. In addition, western blotting could be performed for 
other components of BCAAs metabolism. For example, branched-chain aminotransferase 1 
and 2 (BCAT1 and BCAT2), which catalyse BCAAs catabolism in cytosol and mitochondria 
respectively (158).  
4.5.4.2. Insulin increases proline synthesis  
Proline metabolism is an important aspect of metabolic reprogramming in tumour cells. 
Although only a few studies have explored proline metabolism in colorectal cancer, there is a 
large body of evidence for its importance obtained from the models of other tumours (160) 
(161) (162). Proline catabolism has been found to promote breast cancer cells proliferation in 
3D cell cultures (162). In addition, proline catabolism has been shown to be increased in 
metastatic breast cancer cells compared to primary tumour cells (162).  
Data obtained from SITA showed an increase in labelled proline in early adenoma cells in 
response to insulin stimulation. In addition, the results of glutamine MID analysis showed that 
the largest proportion of proline was the m+5 mass isotopalogue. This suggests that proline is 
synthesized from glutamine in the cells. Proline can be synthesized from glutamate by a 
process catalysed by P5C synthase (P5CS) and P5C reductase (PYCR) and mediated by 
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pyrroline-5-carboxylate (P5C) (163). In addition, proline can be converted back to glutamate 
by a two-step reaction catalysed by POX/PRODH and P5C dehydrogenase (P5CDH) (163). 
Proline catabolism is normally triggered by stress factors such as inflammation or nutrient 
deprivation and results in cell cycle arrest and initiation of apoptosis (163). Due to the fact that 
the POX/PRODH enzyme catalyses the first step of proline catabolism it acts as a metabolic 
tumour suppressor. POX/PRODH is expressed at low levels in tumour cells and has been 
shown to inhibit tumour growth when expressed in a mouse xenograft tumour model (163). It 
has been found by Lui et.al that mutations in the myc oncogene can affect proline and 
glutamate interconversion (163). Myc is able to supress the expression of POX/PRODH and 
in this way promote tumour growth (163).   
It is possible that insulin stimulates expression of myc in early adenoma cells. As a 
consequence myc inhibits the expression of POX/PRODH and promotes proliferation in early 
adenoma cells. Adenocarcinoma cells may already harbour a mutation in myc so insulin 
treatment does not affect the amount of proline present in those cells.   
4.6. Summary 
The results presented in this chapter show that insulin treatment promotes metabolic 
reprogramming in colorectal tumour cells. First of all, insulin increases Warburg effect in both 
early and late stage cells. This effect may be explained by insulin increasing PDK1 expression 
in those cell lines. As mention in chapter 1, PDK1 is a known target of HIF1α, which can be 
activated by insulin signalling. Therefore, it is possible that insulin promotes Warburg effect via 
this pathway. Another aspect of metabolism, which is influenced by insulin treatment is 
glutamine anaplerosis. Interestingly, insulin is increasing glutamine anaplerosis exclusively in 
early adenoma cell line. Similarly, insulin increases amino acids abundance in only early 
adenoma cell line. The specific changes to glutamine anaplerosis and amino acid uptake may 














Appendix to Figure 12. Proliferative response of an adenoma derived cell line series 
















Appendix to Figure 14. The effects of insulin treatment on Akt signalling in colorectal 
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